UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q



ý	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~June 30, ~~2017~~2018



¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-33989

LHC GROUP, INC.

(Exact name of registrant as specified in its charter)



Delaware		71-0918189
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

901 Hugh Wallis Road South

Lafayette, LA 70508

(Address of principal executive offices including zip code)

(337) 233-1307

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ý No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” ~~and~~ “smaller reporting company”, and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Table of Contents

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

~~Table of Contents~~

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No ý

Number of shares of common stock, par value $0.01, outstanding as of ~~November 1, 2017: 18,279,658~~July 30, 2018: 31,333,150 shares.

Table of Contents

LHC GROUP, INC.

INDEX



		Page
Part I. Financial Information
Item 1.	Condensed Consolidated Financial Statements (Unaudited)
Condensed Consolidated Balance Sheets — ~~September~~June 30, ~~2017~~2018 and December 31, ~~2016~~2017		4
Condensed Consolidated Statements of Income — Three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and ~~2016~~2017		5
Condensed Consolidated Statement of Changes in Equity — ~~Nine~~Six months ended ~~September~~June 30, ~~2017~~2018		6
Condensed Consolidated Statements of Cash Flows — ~~Nine~~Six months ended ~~September~~June 30, ~~2017~~2018 and ~~2016~~2017		7
Notes to Condensed Consolidated Financial Statements		8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20 26
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	3540
Item 4.	Controls and Procedures	3540
Part II. Other Information
Item 1.	Legal Proceedings	3641
Item 1A.	Risk Factors	3641
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	3642
Item 6.	Exhibits	3743
Signatures		3844

PART I — FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.

LHC GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except share data)


	September 30, 2017			December 31, 2016			June 30, 2018			December 31, 2017
	(Unaudited)						(Unaudited)
ASSETS
Current assets:
Cash	$	16,922		$	3,264		$	15,370		$	2,849
Receivables:
Patient accounts receivable, less allowance for uncollectible accounts of $26,089 and $29,036, respectively	145,508			124,803
Patient accounts receivable							280,490			161,898
Other receivables	4,705			5,115			7,647			3,163
Amounts due from governmental entities	830			942			830			830
Total receivables, net	151,043			130,860
Total receivables							288,967			165,891
Prepaid income taxes	4,879			—			5,086			7,006
Prepaid expenses	11,437			9,821			23,713			13,042
Other current assets	7,331			5,796			17,300			12,177
Total current assets	191,612			149,741			350,436			200,965
Property, building and equipment, net of accumulated depreciation of $41,876 and $35,226, respectively	47,562			43,251
Property, building and equipment, net of accumulated depreciation of $49,173 and $43,565, respectively							64,898			46,453
Goodwill	392,689			307,317			1,118,777			392,601
Intangible assets, net of accumulated amortization of $12,607 and $10,968, respectively	130,779			102,006
Intangible assets, net of accumulated amortization of $14,094 and $13,041, respectively							325,137			134,610
Assets held for sale							2,850			—
Other assets	2,411			11,756			19,572			19,073
Total assets	$	765,053		$	614,071		$	1,881,670		$	793,702
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and other accrued liabilities	$	40,355		$	26,805		$	76,800		$	39,750
Salaries, wages, and benefits payable	53,289			34,265			99,881			44,747
Self-insurance reserve	9,524			10,691			26,332			12,450
Current portion of long-term debt	261			252			12,617			286
Amounts due to governmental entities	4,564			4,955			4,375			5,019
Income tax payable	—			3,499
Total current liabilities	107,993			80,467			220,005			102,252
Deferred income taxes	38,186			31,941			34,022			27,466
Income taxes payable							3,851			—
Revolving credit facility	119,000			87,000			242,000			144,000
Long-term debt, less current portion	93			544
Long term notes payable							265			—
Total liabilities	265,272			199,952			500,143			273,718
Noncontrolling interest — redeemable	13,206			12,567			17,032			13,393
Stockholders’ equity:
LHC Group, Inc. stockholders’ equity:
Common stock — $0.01 par value; 40,000,000 shares authorized; 22,635,322 and 22,429,041 shares issued in 2017 and 2016, respectively	226			224
Treasury stock — 4,890,181 and 4,828,679 shares at cost, respectively	(42,226		)	(39,135		)
Preferred stock – $0.01 par value; 5,000,000 shares authorized; none issued or outstanding							—			—
Common stock — $0.01 par value; 60,000,000 and 40,000,000 shares authorized in 2018 and 2017, respectively; 35,592,424 and 22,640,046 shares issued in 2018 and 2017, respectively							355			226
Treasury stock — 4,953,665 and 4,890,504 shares at cost, respectively							(46,344		)	(42,249		)
Additional paid-in capital	125,208			119,748			923,655			126,490
Retained earnings	345,967			314,289			386,193			364,401
Total LHC Group, Inc. stockholders’ equity	429,175			395,126			1,263,859			448,868
Noncontrolling interest — non-redeemable	57,400			6,426			100,636			57,723
Total equity	486,575			401,552			1,364,495			506,591
Total liabilities and equity	$	765,053		$	614,071		$	1,881,670		$	793,702

See accompanying notes to condensed consolidated financial statements.

LHC GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Amounts in thousands, except share and per share data)

(Unaudited)


	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016			2018			2017			2018			2017
Net service revenue	$	272,872		$	230,797		$	779,700		$	679,380		$	502,024		$	257,535		$	793,078		$	501,784
Cost of service revenue	172,856			140,832			488,384			413,561			329,646			161,158			518,264			315,528
Gross margin	100,016			89,965			291,316			265,819			172,378			96,377			274,814			186,256
Provision for bad debts	3,194			3,275			8,238			11,658
General and administrative expenses	75,669			66,999			221,077			201,296			141,350			73,552			233,381			145,563
(Gain) loss on disposal of assets	(177		)	142			(23		)	1,389
Operating income	21,330			19,549			62,024			51,476			31,028			22,825			41,433			40,693
Interest expense	(995		)	(816		)	(2,615		)	(2,167		)	(3,202		)	(840		)	(4,652		)	(1,620		)
Income before income taxes and noncontrolling interest	20,335			18,733			59,409			49,309			27,826			21,985			36,781			39,073
Income tax expense	7,445			6,562			20,410			15,500			7,170			7,792			8,147			12,965
Net income	12,890			12,171			38,999			33,809			20,656			14,193			28,634			26,108
Less net income attributable to noncontrolling interests	1,984			2,555			7,321			7,043			3,859			2,889			6,842			5,337
Net income attributable to LHC Group, Inc.’s common stockholders	$	10,906		$	9,616		$	31,678		$	26,766		$	16,797		$	11,304		$	21,792		$	20,771
Earnings per share attributable to LHC Group, Inc.'s common stockholders:
Basic	$	0.61		$	0.55		$	1.79		$	1.53		$	0.55		$	0.64		$	0.90		$	1.17
Diluted	$	0.61		$	0.54		$	1.77		$	1.52		$	0.55		$	0.63		$	0.89		$	1.16
Weighted average shares outstanding:
Basic	17,740,818			17,588,163			17,704,561			17,546,773			30,497,501			17,728,567			24,178,781			17,686,134
Diluted	18,010,522			17,719,473			17,931,700			17,664,284			30,742,293			17,964,387			24,403,310			17,911,723

See accompanying notes to the condensed consolidated financial statements.

LHC GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

(Amounts in thousands, except share data)

(Unaudited)


	Common Stock								Additional Paid-In Capital			Retained Earnings		Noncontrolling Interest Non Redeemable			Total Equity			Common Stock								Additional Paid-In Capital			Retained Earnings		Noncontrolling Interest Non Redeemable			Total Equity
	Issued			Treasury																Issued			Treasury
	Amount		Shares	Amount			Shares													Amount		Shares	Amount			Shares
Balance as of December 31, 2016	$	224	22,429,041	$	(39,135	)	(4,828,679	)	$	119,748		$	314,289	$	6,426		$	401,552
Balance as of December 31, 2017																				$	226	22,640,046	$	(42,249	)	(4,890,504	)	$	126,490		$	364,401	$	57,723		$	506,591
Net income (1)	—		—	—			—		—			31,678		(328		)	31,350			—		—	—			—		—			21,792		1,987			23,779
Acquired noncontrolling interest	—		—	—			—		—			—		52,492			52,492			—		—	—			—		—			—		36,474			36,474
Noncontrolling interest distributions	—		—	—			—		—			—		(1,472		)	(1,472		)	—		—	—			—		—			—		(1,119		)	(1,119		)
Sale of noncontrolling interest	—		—	—			—		348			—		282			630
Purchase of additional controlling interest	—		—	—			—		(184		)	—		—			(184		)
NCI activity																				—		—	—			—		(2,664		)	—		5,571			2,907
Nonvested stock compensation	—		—	—			—		4,522			—		—			4,522			—		—	—			—		3,919			—		—			3,919
Issuance of vested stock	2		191,463	—			—		(2		)	—		—			—
Restricted stock vesting																				2		176,385	—			—		(2		)	—		—			—
Treasury shares redeemed to pay income tax	—		—	(3,091		)	(61,502	)	—			—		—			(3,091		)	—		—	(4,095		)	(63,161	)	—			—		—			(4,095		)
Merger consideration																				127		12,765,288	—			—		795,278			—		—			795,405
Issuance of common stock under Employee Stock Purchase Plan	—		14,818	—			—		776			—		—			776			—		10,705	—			—		634			—		—			634
Balance as of September 30, 2017	$	226	22,635,322	$	(42,226	)	(4,890,181	)	$	125,208		$	345,967	$	57,400		$	486,575
Balance as of June 30, 2018																				$	355	35,592,424	$	(46,344	)	(4,953,665	)	$	923,655		$	386,193	$	100,636		$	1,364,495


(1)	Net income excludes net income attributable to noncontrolling interest-redeemable of ~~$7.6~~$4.9 million during the ~~nine~~six months ending ~~September~~June 30, ~~2017.~~2018. Noncontrolling interest-redeemable is reflected outside of permanent equity on the condensed consolidated balance sheets. See Note 89 of the Notes to Condensed Consolidated Financial Statements.

See accompanying notes to condensed consolidated financial statements.

LHC GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in thousands)

(Unaudited)


	Nine Months Ended September 30,						Six Months Ended June 30,
	2017			2016			2018			2017
Operating activities:
Net income	$	38,999		$	33,809		$	28,634		$	26,108
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization expense	9,680			9,024			7,548			6,348
Provision for bad debts	8,238			11,658
Stock-based compensation expense	4,522			3,518			3,919			3,077
Deferred income taxes	6,245			6,062			1,714			2,522
Gain (loss) on disposal of assets	(23		)	1,389
(Loss) gain on disposal of assets							(126		)	154
Impairment of intangibles and other	81			—			778			—
Changes in operating assets and liabilities, net of acquisitions:
Receivables	(19,569		)	(21,175		)	(18,897		)	(1,926		)
Prepaid expenses and other assets	(3,859		)	450			(6,521		)	(2,329		)
Prepaid income taxes	(4,879		)	(2,482		)	4,624			(3,296		)
Accounts payable and accrued expenses	26,038			17,633			8,729			15,119
Income taxes payable	(3,499		)	—			—			(3,499		)
Net amounts due to/from governmental entities	(279		)	(2,043		)	(704		)	498
Net cash provided by operating activities	61,695			57,843			29,698			42,776
Investing activities:
Purchases of property, building and equipment	(7,944		)	(14,576		)	(13,760		)	(5,341		)
Cash paid for acquisitions, primarily goodwill and intangible assets	(61,247		)	(20,332		)
Other	—			273
Cash acquired from business combination, net of cash paid							13,086			(22,704		)
Advanced payments on acquisitions							—			(523		)
Net cash used in investing activities	(69,191		)	(34,635		)	(674		)	(28,568		)
Financing activities:
Proceeds from line of credit	63,000			38,000			270,084			19,000
Payments on line of credit	(31,000		)	(44,000		)	(278,884		)	(22,000		)
Proceeds from employee stock purchase plan	776			663			634			469
Payments on debt	(192		)	(156		)	135			(129		)
Payments on deferred financing fees							(1,881		)	—
Noncontrolling interest distributions	(8,406		)	(6,859		)	(5,763		)	(5,167		)
Excess tax benefits from vesting of stock awards	—			1,293
Withholding taxes paid on stock-based compensation	(3,091		)	(1,931		)	(4,095		)	(2,744		)
Purchase of additional controlling interest	(184		)	—			(55		)	(184		)
Sale of noncontrolling interest	251			52			3,322			251
Proceeds from exercise of stock options	—			109
Net cash (used in) provided by financing activities	21,154			(12,829		)
Net cash used in financing activities							(16,503		)	(10,504		)
Change in cash	13,658			10,379			12,521			3,704
Cash at beginning of period	3,264			6,139			2,849			3,264
Cash at end of period	$	16,922		$	16,518		$	15,370		$	6,968
Supplemental disclosures of cash flow information:
Interest paid	$	2,694		$	2,329		$	3,112		$	1,762
Income taxes paid	$	22,376		$	11,390		$	2,139		$	17,320

See accompanying notes to condensed consolidated financial statements.

LHC GROUP, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Organization

LHC Group, Inc. (the “Company”) is a health care provider specializing in the post-acute continuum of care. The Company provides home health services, hospice services, home and community-based services, ~~and~~ facility-based services, the latter primarily through long-term acute care hospitals (“LTACHs”), and healthcare innovations services ("HCI").

On April 1, 2018, the Company completed its previously announced "merger of equals" business combination (the "Merger") with Almost Family, Inc. ("Almost Family"). See Note 3 of the Notes to Condensed Consolidated Financial Statements.

As of ~~September~~June 30, ~~2017,~~2018, the Company, through its wholly- and majority-owned subsidiaries, equity joint ventures, controlled affiliates, and management agreements (including, as a result of the Merger, those owned and operated ~~449~~by Almost Family), operated 777 service providers in 2737 states within the continental United States.

Unaudited Interim Financial Information

The accompanying unaudited condensed consolidated balance sheets as of ~~September~~June 30, ~~2017~~2018 and December 31, ~~2016,~~2017, and the related unaudited condensed consolidated statements of income for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and ~~2016,~~2017, condensed consolidated statement of changes in equity for the ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2018, condensed consolidated statements of cash flows for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and ~~2016~~2017, and related notes (collectively, these financial statements are referred to as the "interim financial statements" and together with the related notes are referred to herein as the “interim financial information”) have been prepared by the Company. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been included. Operating results for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 are not necessarily indicative of the results that may be expected for the year ending December 31, ~~2017.~~2018.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented. This report should be read in conjunction with the Company’s consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2016.~~2017. The report was filed with the Securities and Exchange Commission (the “SEC”) on March ~~9, 2017,~~1, 2018, and includes information and disclosures not included herein.

The accompanying unaudited condensed consolidated statements of income for the three and six months ended June 30, 2018, include the results of operations for Almost Family for the period April 1, 2018 to June 30, 2018. The accompanying unaudited condensed consolidated balance sheet at June 30, 2018 includes the preliminary valuation of the assets acquired and liabilities assumed in connection with the Merger. See Note 3 of the Notes to Condensed Consolidated Financial Statements.

2. Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported revenue and expenses during the reporting period. Actual results could differ from those estimates.

Critical Accounting Policies

The Company’s most critical accounting policies relate to the principles of consolidation and revenue ~~recognition, and accounts receivable and allowances for uncollectible accounts.~~recognition.

Principles of Consolidation

The interim financial information includes all subsidiaries and entities controlled by the Company through direct ownership of majority interest or controlling member ownership of such ~~entities.~~entities (including, as a result of the Merger, those owned and operated by Almost Family). Third party equity interests in the consolidated joint ventures are reflected as

noncontrolling interests in the Company’s interim financial information. See Note 9 of the Notes to Condensed Consolidated Financial Statements.

The following table summarizes the percentage of net service revenue earned by type of ownership or relationship the Company had with the operating entity:


	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended June 30,				Six Months Ended June 30,
Ownership type	2017		2016		2017		2016		2018		2017		2018		2017
Wholly-owned subsidiaries	50.6	%	57.6	%	52.1	%	57.3	%	59.5	%	53.3	%	55.5	%	53.5	%
Equity joint ventures	47.5		40.7		46.1		41.0		39.4		45.1		43.0		44.8
Other	1.9		1.7		1.8		1.7		1.1		1.6		1.5		1.7
	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%

All significant intercompany accounts and transactions have been eliminated in the Company’s accompanying interim financial information. Business combinations accounted for under the acquisition method have been included in the interim financial information from the respective dates of acquisition.

The Company consolidates equity joint venture entities as the Company has controlling interests in the entities, has voting control over these entities, or has ability to exercise significant influence in the entities. The members of the Company's equity joint ventures participate in profits and losses in proportion to their equity interests. The Company also consolidates entities which have license leasing arrangements as the Company owns 100% of the equity of these subsidiaries.

The Company has various management services agreements under which the Company manages certain operations of agencies. The Company does not consolidate these agencies ~~because~~if the Company does not have an ownership interest in, nor does it have an obligation to absorb losses of, or right to receive benefits from the entities that own the agencies.

Revenue Recognition

Basis of Presentation

The Company ~~reports~~adopted ASU No. 2014-09, Revenue from Contracts with Customers, ("ASU 2014-09") on January 1, 2018 on a full retrospective basis, which required the Company to present the prior comparable period as adjusted. The adoption of the standard did not have a material impact on the Company's interim financial statements. The Company did not adjust the opening balance of retained earnings to account for the implementation of the requirements of this standard as there are no timing differences related to the recognition of implicit price concessions as part of net service revenue. All amounts previously classified as provision for bad debts are now classified within the Company's net service revenue. For the three and six months ended June 30, 2018, the Company recorded $7.7 million and $12.6 million, respectively, of implicit price concessions as a direct reduction of net service revenue that would have been recorded as provision for bad debts prior to the adoption of ASU 2014-09.

Adoption of the standard impacted the Company's previously reported results as follows (amounts in thousands):



	As previously reported			Adjustment for ASU 2014-09			As adjusted
	As of December 31, 2017
Condensed Consolidated Balance Sheets
Patient accounts receivable	$	161,898		$	—		$	161,898
Allowance for uncollectible accounts	23,556			(23,556		)	—
	Three Months Ended June 30, 2017
Condensed Consolidated Statements of Income:
Net service revenue	260,210			(2,675		)	257,535
Provision for bad debts	2,675			(2,675		)	—
Net income attributable to LHC Group, Inc.'s common stockholders	11,304			—			11,304
	Six Months Ended June 30, 2017
Condensed Consolidated Statements of Income:
Net service revenue	506,828			(5,044		)	501,784
Provision for bad debts	5,044			(5,044		)	—
Net income attributable to LHC Group, Inc.'s common stockholders	20,771			—			20,771
Condensed Consolidated Statements of Cash Flows:
Provision for bad debts	5,044			(5,044		)	—
Changes in operating assets and liabilities, net of acquisitions:
Receivables	(6,970		)	5,044			(1,926		)

Net service revenue is reported at the ~~estimated net realizable~~ amount that reflects the consideration to which the Company expects to receive in exchange for providing services. These amounts are due from Medicare, Medicaid, Managed Care, Commercial, and others for services ~~rendered.~~rendered, and they include implicit price concessions for retroactive revenue adjustments due to actual receipts from third-party payors, settlement of audits, and reviews. The estimated uncollectible amounts due from these payors are considered implicit price concessions that are a direct reduction to net service revenue. The Company assesses the patient's ability to pay for their healthcare services at the time of patient admission based on the Company's verification of the patient's insurance coverage under the Medicare, Medicaid, and other commercial or managed care insurance ~~program.~~programs. Medicare contributes to the net service revenue of the Company’s home health, ~~services,~~ hospice, ~~services,~~facility-based, and ~~facility-based~~healthcare innovations services. Medicaid and other payors contribute to the net service revenue of all of the Company's ~~services.~~segments.

Performance obligations are determined based on the nature of the services provided by the Company. The majority of the Company's performance obligation is to provide services to each patient based on medical necessity and identifies the bundle of services to be provided to achieve the goals established in the contract, while the healthcare innovations segment's performance obligation is largely to provide services under customer contracts. Revenue for performance obligations is satisfied over time and recognized based on actual charges incurred in relation to total expected charges over the measurement period of the performance obligation, which depicts the transfer of services and related benefits received by the patient and customers over the term of the contract to satisfy the obligations. The Company measures the satisfaction of the performance obligation as services are provided.

The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 - Revenue Recognition, and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged.

The Company determines the transaction price based on gross charges for services provided, reduced by contractual adjustments provided to third-party payors and implicit price concessions. The Company determines estimates of contractual adjustments and implicit price concessions based on historical collection experience. Estimates of contractual allowance and implicit price concessions are periodically reviewed to ensure they encompass the Company's current contract terms, are reflective of the Company's current patient mix, and are indicative of the Company's historic collections to ensure net service revenue is recognized at its net realizable value.

The following table sets forth the percentage of net service revenue earned by category of payor for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and ~~2016:~~2017:


	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended June 30,				Six Months Ended June 30,
Payor:	2017		2016		2017		2016
									2018		2017		2018		2017
Home health:
Medicare	71.0	%	74.3	%	71.5	%	74.7	%	72.9	%	72.4	%	72.3	%	73.0	%
Medicaid	1.8		1.9		1.8		1.8		1.5		1.2		1.3		1.2
Managed Care, Commercial, and Other	27.2		23.8		26.7		23.5		25.6		26.4		26.4		25.8
	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%
Hospice:
Medicare									91.1	%	92.9	%	91.7	%	93.5	%
Medicaid									0.6		0.9		0.6		0.6
Managed Care, Commercial, and Other									8.3		6.2		7.7		5.9
									100.0	%	100.0	%	100.0	%	100.0	%
Home and Community-Based Services:
Medicaid									24.7	%	18.0	%	23.1	%	17.3	%
Managed Care, Commercial, and Other									75.3		82.0		76.9		82.7
									100.0	%	100.0	%	100.0	%	100.0	%
Facility-Based Services:
Medicare									58.7	%	65.0	%	61.4	%	64.4	%
Medicaid									—		—		—		—
Managed Care, Commercial, and Other									41.3		35.0		38.6		35.6
									100.0	%	100.0	%	100.0	%	100.0	%
HCI:
Medicare									26.7	%	—	%	26.7	%	—	%
Medicaid									0.4		—		0.4		—
Managed Care, Commercial, and Other									72.9		—		72.9		—
									100.0	%	—	%	100.0	%	—	%

Medicare

Home Health Services

The ~~Company’s~~ home ~~nursing~~health segment's Medicare patients, including certain Medicare Advantage patients, are classified into one of 153 home health resource groups prior to receiving services. Based on the patient’s home health resource group, the Company is entitled to receive a standard prospective Medicare payment for delivering care over a 60-day period referred to as an episode. The Company elects to use the same 60-day length of episode that Medicare recognizes as standard but accelerates revenue upon discharge to align with a patient's episode length, if less than the expected 60 days, which depicts the transfer of services and related benefits received by the patient over the term of the contract necessary to satisfy the obligations. The Company recognizes revenue based on the number of days elapsed during an episode of care within the reporting period.

Final payments from Medicare will reflect base payment adjustments for case-mix and geographic wage differences and 2% sequestration ~~reduction for episodes beginning after March 31, 2013.~~reduction. In addition, final payments may reflect one of four retroactive adjustments to ~~ensure the adequacy and effectiveness of~~ the total reimbursement: (a) an outlier payment if the patient’s care was unusually costly; (b) a low utilization adjustment if the number of visits was fewer than five; (c) a partial payment if the patient transferred to another provider before completing the episode; or (d) a payment adjustment based upon the level of therapy services required. ~~Adjustments~~The retroactive adjustments outlined above are ~~automatically~~ recognized in net service revenue when

~~changes occur~~ the event causing the adjustment occurs and during the period in which the services are provided to the patient. The Company reviews these adjustments to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustments is subsequently resolved. Net service revenue and related patient accounts receivable are recorded at amounts estimated to be realized from Medicare for services rendered.

Hospice Services

~~Hospice~~The Company's hospice services ~~provided by the Company are paid~~segment is reimbursed by Medicare under a per diem payment ~~system.~~system based on the determined need for the patient on a daily basis. The ~~Company~~hospice segment receives one of four predetermined daily rates based upon the level of care the Company furnishes. Each level of care is contingent upon the patient's medical necessity and is distinct under contracted performance obligation, which depicts the transfer of services and related benefits received by the patient over the term of the contract to satisfy the obligations. The Company records net service revenue ~~from~~for hospice services based on the ~~daily or hourly~~contracted per diem rate ~~and recognizes revenue~~over time as ~~hospice~~ services are ~~provided.~~provided, satisfying the performance obligation.

Hospice payments are subject to variable consideration through an inpatient cap and an overall Medicare payment cap. The inpatient cap relates to individual programs receiving more than 20% of ~~its~~their total Medicare reimbursement from inpatient care services, and the overall Medicare payment cap relates to individual providers receiving reimbursements in excess of a “cap amount,” ~~calculated~~determined by ~~multiplying~~Medicare to be payment equal to six months of hospice care for the ~~number~~aggregate base of ~~beneficiaries during the period by a statutory amount that is~~hospice patients, indexed for inflation. The determination for each cap is made annually based on the 12-month period ending on October 31 of each year. The Company monitors its limits on a provider-by-provider basis and records an estimate of its liability for reimbursements received in excess of the cap ~~amount. Beginning~~amount in the reporting period. The Company reviews these estimates to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the cap year October 1, 2014, Center for Medicare and Medicaid Services ("CMS") implemented a new process requiring hospice providers to self-report their cap liabilities and remit applicable payment by March 31 of the following year.retroactive adjustments is subsequently resolved.

Facility-Based Services

The ~~Company~~Company's facility-based services segment is reimbursed primarily by Medicare for services provided under the LTACH prospective payment system. Each LTACH patient is assigned a long-term care diagnosis-related group. The Company is paid a predetermined fixed amount intended to reflect the average cost of treating a Medicare LTACH patient classified in that particular long-term care diagnosis-related group. For selected LTACH patients, the amount may be further adjusted based on length of stay and facility-specific costs, as well as in instances where a patient is discharged and subsequently re-admitted, among other factors. The Company calculates the adjustment based on a historical average of these types of adjustments for LTACH claims paid. Similar to other Medicare prospective payment systems, the rate is also adjusted for geographic wage differences. ~~Revenue~~Net service revenue adjustments resulting from reviews and audits of Medicare cost report settlements are considered implicit price concessions for LTACHs and are measured at expected value. The Company reviews these estimates to ensure that it is probable that a significant reversal in the amount of LTACH services cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustments is subsequently resolved. Net service revenue for the Company’s ~~LTACHs as~~LTACH services are ~~provided.~~satisfied over time and recognized based on actual charges incurred in relation to total expected charges, which depicts the transfer of services and related benefits received by the customer over the term of the contract to satisfy the obligations.

~~Medicaid, managed care,~~Non-Medicare Revenues

Substantially all remaining revenues are derived from services provided under a per visit, per hour or unit basis, per assessment or per member per month basis for which revenues are calculated and ~~other payors~~recorded using payor-specific or patient-specific fee schedules based on the contracted rates in each underlying third party payor or services agreement. Net service revenue is recognized as such services are provided and costs for delivery of such services are incurred.

Contingent Service Revenues

The Company’s ~~Medicaid reimbursement is based on a predetermined fee schedule applied~~Healthcare Innovations segment provides strategic health management services to each service provided. Therefore, revenue is recognized for Medicaid services as services are provided based on this fee schedule. The Company’s managed care and other payors reimburse the Company based upon a predetermined fee schedule or an episodic basis, depending on the terms of the applicable contract. Accordingly, the Company recognizes revenue from managed care and other payorsAccountable Care Organizations (“ACOs”) that have been approved to participate in the ~~same manner as~~Medicare Shared Savings Program (“MSSP.”) The HCI segment has service agreements with ACOs that provide for sharing of MSSP payments received by the ~~Company recognizes~~ACO, if any. ACOs are legal entities that contract with Centers for Medicare and Medicaid Services ("CMS") to provide services to the Medicare fee-for-service population with the goal of providing better care for individuals, improving health for populations and lowering costs. ACOs share savings with CMS to the extent that the actual costs of serving assigned beneficiaries are below certain trended benchmarks of such beneficiaries and certain quality performance measures are achieved. The MSSP is relatively new and therefore has limited historical experience, which impacts the Company’s ability to accurately accumulate and interpret the data available for calculating an ACOs’ shared savings, if any. No net service revenue ~~from Medicare~~has been recognized related to potential MSSP payments for savings generated for the program periods ended December 31, 2017 or ~~Medicaid.~~2018, if any.

Accounts Receivable ~~and Allowances for Uncollectible Accounts~~

The Company reports accounts receivable ~~net of estimated allowances for uncollectible accounts and adjustments.~~at amounts ultimately expected to be collected. Accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors, and patients. To provide for accounts receivable that could become uncollectible in the future, the Company establishes an allowance for uncollectible accounts to reduce the carrying amount of such receivables to their estimated net realizable value. The credit risk for other concentrations of receivables is limited due to the significance of Medicare as the primary payor. The Company believes the credit risk associated with its Medicare accounts, which have historically exceeded 50% of its patient accounts receivable, is limited due to (i) the historical collection rate from Medicare and (ii) the fact that Medicare is a U.S. government payor. The Company does not believe that there are any other concentrations of receivables from any particular payor that would subject it to any significant credit risk in the collection of accounts receivable.

The amount of the provision for bad debts is based upon the Company’s assessment of historical and expected net collections, business and economic conditions, and trends in government reimbursement. Uncollectible accounts are written off when the Company has determined the account will not be collected.

A portion of the estimated Medicare prospective payment system reimbursement from each submitted home nursing episode is received in the form of a request for anticipated payment (“RAP”). The Company submits a RAP for 60% of the

estimated reimbursement for the initial episode at the start of care. The full amount of the episode is billed after the episode has been completed. The RAP ~~received~~is recouped and the payment for ~~that particular~~the entire episode is ~~deducted from the final payment.~~paid. If a final bill is not submitted within the greater of 120 days from the start of the episode, or 60 days from the date the RAP was paid, any RAP received for that episode will be recouped by Medicare from any other Medicare claims in process for that particular provider. The RAP and final claim must then be resubmitted. For subsequent episodes of care contiguous with the first episode for a particular patient, the Company submits a RAP for 50% instead of 60% of the estimated reimbursement.

The Company’s Medicare population is paid at prospectively set amounts that can be determined at the time services are rendered. The Company’s Medicaid reimbursement is based on a predetermined fee schedule applied to each individual service it provides. The Company’s managed care contracts are structured ~~similar~~similarly to either the Medicare or Medicaid payment methodologies. The Company is able to calculate its actual amount due at the patient level and adjust the gross charges down to the actual amount at the time of billing. This negates the need to record an estimated contractual allowance when reporting net service revenue for each reporting period.

Other Significant Accounting Policies

Earnings Per Share

Basic per share information is computed by dividing the relevant amounts from the condensed consolidated statements of income by the weighted-average number of shares outstanding during the period, under the treasury stock method. Diluted per share information is also computed using the treasury stock method, by dividing the relevant amounts from the condensed consolidated statements of income by the weighted-average number of shares outstanding plus potentially dilutive shares.

The following table sets forth shares used in the computation of basic and diluted per share ~~information:~~information and, with respect to the data provided for the three and six months ended June 30, 2018, includes shares of the Company issued to former stockholders of Almost Family in connection with the Merger. See Note 3 of the Notes to Condensed Consolidated Financial Statements:


	Three Months Ended September 30,		Nine Months Ended September 30,		Three Months Ended June 30,		Six Months Ended June 30,
	2017	2016	2017	2016	2018	2017	2018	2017
Weighted average number of shares outstanding for basic per share calculation	17,740,818	17,588,163	17,704,561	17,546,773	30,497,501	17,728,567	24,178,781	17,686,134
Effect of dilutive potential shares:
Options	—	—	—	1,146
Nonvested stock	269,704	131,310	227,139	116,365	244,792	235,820	224,529	225,589
Adjusted weighted average shares for diluted per share calculation	18,010,522	17,719,473	17,931,700	17,664,284	30,742,293	17,964,387	24,403,310	17,911,723
Anti-dilutive shares	—	20,001	137,400	214,856	20,200	—	236,037	149,100

Effective April 1, 2018, in conjunction with the Merger, the Company increased the authorized number of common shares to 60.0 million.

Assets Held for Sale

As of June 30, 2018, assets held for sale includes the land and building and all related equipment and fixtures of one closed hospice facility, which was acquired in the Merger that the Company is actively marketing and intends to sell.

Recently Adopted Accounting Pronouncements

~~In March 2016, as part of its Simplification Initiative, the FASB issued ASU No. 2016-09,~~ ~~Compensation - Stock Compensation~~ ("ASU 2016-09"), which seeks to reduce complexity in accounting standards. The areas for simplification in ASU 2016-09, involve several aspects of the accounting for share-based payment transaction, including (1) accounting for income taxes, (2) classification of excess tax benefits on the statement of cash flow, (3) forfeitures, (4) minimum statutory tax withholding requirements, (5) classification of employee taxes paid on the statement of cash flows when an employer withholds shares for tax withholding purposes, (6) the practical expedient for estimating the expected term, and (7) intrinsic value. The Company adopted the new standard on its effective date on January 1, 2017 and elected to apply this adoption prospectively.

All excess tax benefits and deficiencies in the current and future periods will be recognized as income tax expense in the Company's consolidated financial statements in the reporting period in which they occur. The Company recorded excess tax benefits of $1.0 million in income tax expense for the nine months ended September 30, 2017. Additionally, the Company elected to continue to apply an estimated rate of forfeiture to its compensation expense for share-based awards.

~~Recently Issued Accounting Pronouncements~~

On May 28, 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, ("ASU 2014-09") which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 ~~will replace~~replaced most existing revenue recognition guidance in U.S. ~~GAAP when~~GAAP. The Company adopted the new standard on January 1, 2018, and elected to adopt it ~~becomes effective. The new standard~~using the full retrospective method.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments, which addresses eight classification issues related to the statement of cash flows. This ASU is effective for ~~reporting~~annual and interim periods in fiscal years beginning after December 15, 2017. Early adoption is permitted, including adoption in an interim period. Entities should apply this ASU using a retrospective transition method to each period presented. There is no material impact to the Company's interim financial statements upon adoption of ASU 2016-15.

In January 2017, the FASB issued ASU 2017-01, Business Combinations: Clarifying the Definition of a Business, which assist entities with evaluating whether a set of transferred assets and activities is a business. This ASU is effective for annual and interim period in fiscal years beginning after December 15, 2017. The ~~standard permits~~impact on the ~~use of either the full retrospective or cumulative effect transition method. As the Company progresses with evaluating the effect that ASU 2014-09 will have on its~~Company's consolidated financial statements and related disclosures ~~the Company does not expect a material impact~~will depend on ~~its consolidated financial statements upon implementation on January 1, 2018. Currently, the Company anticipates adopting~~facts and circumstances of any specific future transactions as evaluated under the new ~~standard using the full retrospective method for all periods presented.~~guidance.

Recently Issued Accounting Pronouncements

In February 2016, the FASB issued ASU No. 2016-02, Leases, ("ASU 2016-02") which requires lessees to recognize qualifying leases on the statement of financial position. Qualifying leases will be classified as right-of-use assets and lease liabilities. The new standard is effective on January 1, 2019. Early adoption is permitted. ASU 2016-02 mandates a modified retrospective transition method for all entities. The Company anticipates that the adoption of ASU 2016-02 will result in a ~~material~~significant increase in total assets and total liabilities. The Company continues to evaluate the effect that ASU 2016-02 will have on its related disclosures.

In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment, which requires an entity to no longer perform a hypothetical purchase price allocation to measure goodwill impairment. Instead, impairment will be measured using the difference between the carrying amount and the fair value of the reporting unit. This ASU is effective for annual and interim periods in fiscal years beginning after December 15, 2019. Early adoption is permitted for goodwill impairment tests with measurement dates on or after January 1, 2017.

3. Almost Family Merger

On April 1, 2018, the Company completed its previously announced merger of equals business combination with Almost Family as contemplated by that certain Agreement and Plan of Merger, dated as of November 15, 2017 by merging Hammer Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), with and into Almost Family, with Almost Family continuing as the surviving entity in the Merger and as a wholly owned subsidiary of the Company. At the effective time of the Merger on April 1, 2018, each outstanding share of common stock of Almost Family, other than certain canceled shares, was converted into the right to receive 0.9150 shares of the Company’s common stock and cash in lieu of any fractional shares of any Company common stock that Almost Family shareholders would otherwise have been entitled to receive. As a result, the Company issued approximately 12.8 million shares of its common stock to former stockholders of Almost Family. The Company was determined to be the accounting acquirer in the Merger.

The following table summarizes the consideration transferred in connection with the Merger (amounts in thousands, except share data):



Outstanding shares of Almost Family common stock as of April 1, 2018	13,951,134
Exchange ratio	0.9150
Shares of the Company issued	12,765,288
Price per share as of April 1, 2018	$	61.56
Fair value of the Company common stock issued	$	785,831
Fair value of vested Almost Family equity awards exchanged for equity awards in the Company	$	9,581
Preliminary merger consideration	$	795,412

The Company's preliminary valuation analysis of identifiable assets and liabilities assumed for the Merger is in accordance with the requirements of ASC Topic 805, Business Combinations, the preliminary estimates of which are presented in the table below (amounts in thousands). The final determination of the fair value of assets acquired and liabilities assumed will be completed in accordance with the applicable accounting guidance. Due to the significance of the Merger, the Company may use all of the measurement period to adequately analyze and assess the fair values of assets acquired and liabilities assumed.



Preliminary merger consideration
Stock	$	795,412
Preliminary fair value of total consideration transferred
Recognized amounts of identifiable assets acquired and liabilities assumed:
Cash and cash equivalents	$	16,547
Patient accounts receivable	101,933
Prepaid income taxes	2,705
Prepaid expenses and other current assets	9,540
Property and equipment	11,144
Trade name	116,679
Certificates of need/licenses	58,861
Other identifiable intangible assets	15,856
Assets held for sale	2,850
Accounts payable	(38,202		)
Accrued other liabilities	(59,041		)
Deferred income taxes	(4,842		)
Seller notes payable	(12,461		)
NCI- Redeemable	(2,256		)
Long term income taxes payable	(3,786		)
Line of credit	(106,800		)
NCI- Nonredeemable	(34,990		)
Other assets and (liabilities), net	252
Total identifiable assets and liabilities	73,989
Preliminary goodwill	$	721,423

The following unaudited pro forma financial information reflects the consolidated results of operations of the Company had the Merger occurred on January 1, 2017. Almost Family’s financial information has been compiled in a manner consistent with the accounting policies adopted by LHC Group. The unaudited pro forma financial information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the merger occurred on January 1, 2017, nor are they indicative of any future results (amounts in thousands, except per share amount).



	Pro forma - unaudited
	Six months ended June 30,
	2018		2017
Net service revenue	$	997,043	$	896,827
Net income attributable to the Company	37,652		29,181
Diluted earnings per share	$	1.22	$	0.95

The pro forma financial information contained in this report, including the above, is based on the Company's preliminary assignment of consideration given and therefore subject to adjustment. These pro forma amounts were calculated after applying the Company’s accounting policies and adjusting Almost Family’s and LHC Group's results to reflect adjustments that are directly attributable to the Merger. These adjustments mainly exclude transaction costs incurred by Almost Family and LHC Group in the fiscal quarter preceding the consummation of the Merger, together with the consequential tax effects at the statutory rate.

The unaudited pro forma financial information contained in this report, including the above, has been prepared for informational purposes only and does not include any anticipated synergies or other potential benefits of the Merger. Pro forma information is not presented for any other acquisitions or joint venture transactions, as the aggregate operations of the acquired businesses were not significant to the overall operations of the Company. It also does not give effect to certain future charges that the Company expects to incur in connection with the Merger, including, but not limited to, additional professional fees, legal expenses, severance, retention and other employee-related costs, contract breakage costs, and costs related to consolidation of technology systems and corporate facilities.

Transaction costs associated with the Merger that were incurred by the Company during the six months ended June 30, 2018 are being expensed as incurred and are presented in the condensed consolidated statements of income as general and administrative expenses. These expenses include investment banking, legal, accounting, and other third party transaction costs associated with the Merger, including preparation for regulatory filings and shareholder approvals. During the six months ended June 30, 2018, the Company incurred $11.7 million of transaction costs related to the Merger.

4. Other Acquisitions and Joint ~~Ventures~~Venture Activities

On January 1, 2017, the Company formed a joint venture with LifePoint Health, Inc. ("LifePoint"). LifePoint contributed 28 home health agencies, 12 hospice agencies, and one inpatient hospice unit to the joint venture during the nine months ended September 30, 2017. The Company acquired ~~majority ownership~~the majority-ownership of the membership interests of these agencies. These providers conduct home health operations in Arizona, Colorado, Louisiana, Michigan, North Carolina, Pennsylvania, Tennessee, Texas, and Virginia; and hospice operations in Michigan, North Carolina, Pennsylvania, Tennessee, and Virginia.

~~On June 1, 2017, the Company formed a joint venture with Baptist Memorial Health Care ("Baptist"). Baptist contributed~~ three home health agencies Nason Home Health in Roaring Springs, Pennsylvania, 1st Choice Home Health Care in Denton, Texas, and ~~six hospice agencies to the joint venture~~Prime Healthcare Services in Reno, Nevada during the ~~nine~~six months ended ~~September~~June 30, ~~2017. The Company acquired majority ownership of the membership interests of these agencies. These providers conduct home health and hospice operations in Mississippi and Tennessee.~~

On September 1, 2017, the Company formed a joint venture with Christus Continuing Care (“Christus”). Christus contributed seven home health agencies, five hospice agencies, one inpatient hospice unit, one community-based agency, and six LTACH agencies to the joint venture during the nine months ended September 30, 2017. The Company acquired majority ownership of the membership interests of these agencies. These providers conduct home health, hospice, and community-based operations in Louisiana and Texas; and LTACH operations in Arkansas, Louisiana, and Texas.

~~In separate transactions, the Company acquired two home health agencies, two hospice agencies, one inpatient hospice unit, and one pharmacy during the nine months ended September 30, 2017.~~

2018. The total aggregate purchase price for these transactions was ~~$76.7~~$3.6 million, of which ~~$10.4 million was paid in December 2016 and $61.2~~$3.5 million was primarily paid in ~~cash during the nine months ended September 30, 2017.~~cash. The purchase prices were determined based on the Company’s analysis of comparable acquisitions and the target market’s potential future cash flows. Substantially all of the preliminary allocation of the purchase price for the acquisitions were allocated to goodwill of $4.3 million, indefinite lived intangibles-trade names of $0.6 million, and Certificates of need/licenses of $0.5 million. Acquired noncontrolling interest was $2.1 million.

Goodwill generated from the acquisitions was recognized based on the expected contributions of each acquisition to the overall corporate strategy. The Company expects its portion of goodwill to be fully tax deductible. The acquisitions were accounted for under the acquisition method of accounting. Accordingly, the accompanying interim financial information includes the results of operations of the acquired entities from the date of acquisition.

During the six months ended June 30, 2018, the Company sold ownership interests in four of its wholly-owned subsidiaries. The ~~following table summarizes the aggregate consideration paid~~total purchase prices for the ~~acquisitions and~~sale of such ownership interests were $3.8 million, all of which were accounted for as equity transactions, resulting in the amounts of the assets acquired and liabilities assumed at the acquisition dates, as well as their fair value at the acquisition dates and the noncontrolling interest acquired during the nine months ended September 30, 2017 (amountsCompany reducing additional paid in ~~thousands):~~

Consideration
  Cash $ 71,677
Fair value of total consideration transferred
Recognized amounts of identifiable assets acquired and liabilities assumed:
  Patient accounts receivable 6,532
  Trade name 13,953
  Certificates of need/licenses 16,447
  Other identifiable intangible assets 6
  Other assets and (liabilities), net 2,121
Total identifiable assets 39,059
Noncontrolling interest 52,492
Goodwill, including noncontrolling interest of $34,313 $ 85,110

The Company conducted preliminary assessments and recognized provisional amounts in its initial accounting for the acquisitions of majority ownership of three joint venture partnerships for all identified assets in accordance with the requirements of ASC Topic 805. The Company is continuing its review of these matters during the measurement period. If new information about facts and circumstances that existed at the acquisition date is obtained and indicates adjustments are necessary, the acquisition accounting will be revised to adjust to the provisional amounts initially recognized.

capital by $2.7 million.

4.5. Goodwill and Intangibles

The changes in recorded goodwill by reporting unit for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 were as follows (amounts in thousands):

Home health reporting unit
Hospice
reporting unit

Community -
based
reporting unit

Facility-based
reporting unit
Total
Balance as of December 31, 2016 $ 210,839
$ 64,234
$ 18,820
$ 13,424
$ 307,317
Goodwill from acquisitions 29,448
15,188
4,285
1,876
50,797
Goodwill related to noncontrolling interests 20,781
9,674
2,856
1,002
34,313
Goodwill related to disposals (80 ) —
—
—
(80 )
Goodwill related to prior period net working capital adjustments............................................ (5 ) —
—
347
342
Balance as of September 30, 2017 $ 260,983
$ 89,096
$ 25,961
$ 16,649
$ 392,689



	Home health reporting unit		Hospice reporting unit		Home and community-based services reporting unit		Facility-based reporting unit		HCI reporting unit		Total
Balance as of December 31, 2017	$	261,456	$	88,814	$	28,541	$	13,790	$	—	$	392,601
Acquisitions	525,654		25,176		137,882		—		35,484		724,196
Noncontrolling interests	1,576		—		—		—		—		1,576
Prior period adjustments and disposals............................................	—		—		—		404		—		404
Balance as of June 30, 2018	$	788,686	$	113,990	$	166,423	$	14,194	$	35,484	$	1,118,777

The allocation of goodwill from acquisitions for each reporting unit is preliminary and subject to change once the valuation analysis required by ASC 805, Business Combinations is finalized.

Intangible assets consisted of the following as of ~~September~~June 30, ~~2017~~2018 and December 31, ~~2016~~2017 (amounts in thousands):

September 30, 2017
Remaining useful life
Gross
carrying
amount

Accumulated
amortization

Net
carrying
amount
Indefinite-lived assets:

Trade names Indefinite $ 78,590
$ —
$ 78,590
Certificates of need/licenses Indefinite 49,773
—
49,773
Total $ 128,363
$ —
$ 128,363
Definite-lived assets:
Trade names 2 months — 9 years $ 9,291
$ (7,184 ) $ 2,107
Non-compete agreements 2 month — 2 years 5,732
(5,423 ) 309
Total $ 15,023
$ (12,607 ) $ 2,416
Balance as of September 30, 2017 $ 143,386
$ (12,607 ) $ 130,779



	Indefinite lived assets					Definite lived assets
	Trade Names		Certificates of Need			Trade Names			Customer Relationships			Non-compete			Total
Balance as of December 31, 2017	$	78,299	$	53,493		$	2,580		$	—		$	238		$	134,610
Acquisitions	117,349		59,056			—			15,856			91			192,352
Amortization	—		—			(739		)	(127		)	(188		)	(1,054		)
Adjustments & disposals	—		(771		)	—			—			—			(771		)
Balance as of June 30, 2018	$	195,648	$	111,778		$	1,841		$	15,729		$	141		$	325,137

Remaining useful lives for trade names, customer relationships, and non-compete agreements were 9.3, 19.8 and 3.1 years, respectively, at June 30, 2018. Similar amounts at December 31, 2017 were 10.3 and 2.1 years for trade names and non-compete agreements, respectively.

December 31, 2016
Remaining useful life
Gross
carrying
amount

Accumulated
amortization

Net
carrying
amount
Indefinite-lived assets:

Trade names Indefinite $ 64,672
$ —
$ 64,672
Certificates of need/licenses Indefinite 33,327
—
$ 33,327
Total $ 97,999
$ —
$ 97,999
Definite-lived assets:
Trade names 8 months — 9 years $ 9,294
$ (5,991 ) $ 3,303
Non-compete agreements 2 months — 3 years 5,681
(4,977 ) 704
Total $ 14,975
$ (10,968 ) $ 4,007
Balance as of December 31, 2016 $ 112,974
$ (10,968 ) $ 102,006

Intangible assets ~~of $87.8 million, net~~(net of accumulated ~~amortization,~~amortization) in the amount of $249.1 million were related to the home health services segment, ~~$31.8~~$35.4 million were related to the hospice services segment, ~~$9.0~~$20.7 million were related to the community-based services segment, ~~and $2.2~~$4.2 million were related to the facility-based services segment, and $15.7 million were related to the HCI services segment as of ~~September~~June 30, ~~2017. The Company recorded $1.6 million and $1.8 million of amortization~~2018. Amortization expense ~~during the nine months ended September 30, 2017 and 2016, respectively. This~~ was recorded in general and administrative expenses.

5.6. Debt

Credit Facility

OnDuring the period from January 1, 2018 through April 1, 2018, the Company maintained its revolving line of credit through a credit facility agreement with Capital One, National Association, which had a scheduled maturity of June 18, ~~2014,~~2019 (the "Prior Credit Facility").

On March 30, 2018, the Company entered into a Credit Agreement with JPMorgan Chase Bank, N.A., which was effective on April 2, 2018 following the Merger (the ~~“Credit Agreement”~~"New Credit Agreement") ~~with Capital One, National Association, which~~. The New Credit Agreement provides a senior, secured revolving line of credit commitment with a maximum principal borrowing limit of ~~$225.0~~$500.0 million,which includes an additional $200.0 million accordion expansion feature, and a letter of credit sub-limit equal to ~~$15.0~~$50.0 million. The expiration date of the New Credit Agreement is March 30, 2023. The New Credit Agreement replaced the Prior Credit Facility with Capital One, National Association, which was set to mature on June 18, 2019. The Company’s obligations under the New Credit Agreement are secured by substantially all of the assets of the Company and its wholly-owned subsidiaries (subject to customary exclusions), which assets include the Company’s equity ownership of its wholly-owned subsidiaries and its equity ownership in joint venture entities. The Company’s wholly-owned subsidiaries also guarantee the obligations of the Company under the New Credit Agreement. Debt issuance costs of $1.9 million were capitalized with the New Credit Agreement and will be amortized through March 30, 2023, the termination date for the New Credit Agreement.

Revolving loans under the New Credit Agreement with JPMorgan Chase Bank, N.A. bear interest at, as selected by the Company, either a ~~(1)~~(a) Base Rate, which is defined as a fluctuating rate per annum equal to the highest of ~~(a)~~(1) the Federal Funds Rate in effect on such day plus 0.5% ~~(b)~~(2) the Prime Rate in effect on such day and ~~(c)~~(3) the Eurodollar Rate for a one month interest period on such day plus ~~1.0%~~1.5%, plus a margin ranging from ~~0.75%~~0.50% to ~~1.5%~~1.25% per annum or ~~(2)~~(b) Eurodollar rate plus a margin ranging from ~~1.75%~~1.50% to ~~2.5%~~2.25% per ~~annum.~~annum, with pricing varying based on the Company's quarterly consolidated Leverage Ratio (as defined in the New Credit Agreement). Swing line loans bear interest at the Base Rate. The Company is limited to 15 Eurodollar borrowings outstanding at ~~the same~~any time. The Company is required to pay a commitment fee for the unused commitments at rates ranging from ~~0.225%~~0.20% to ~~0.375%~~0.35% per annum depending upon the Company’s quarterly consolidated Leverage ~~Ratio, as defined in the Credit Agreement.~~Ratio. The Base Rate ~~at September~~as of June 30, ~~2017~~2018 was ~~5.25%~~5.75% and the ~~Eurodollar~~LIBOR rate was ~~3.24%~~3.88%. As of June 30, 2018, the effective interest rate on outstanding borrowings under the New Credit Agreement was 3.85%.

On April 2, 2018, in connection with the consummation of the Merger, the Company borrowed approximately $247.4 million under the New Credit Agreement to (i) repay the approximately $107.3 million of outstanding borrowings under Almost Family’s $350.0 million credit facility, which was terminated in connection with the Merger, (ii) repay the approximately $125.1 million of outstanding borrowings under Prior Credit Facility, which was also terminated in connection with the Merger, and (iii) pay certain debt issuance and repayment costs and Merger related fees and expenses.

As of ~~September~~June 30, ~~2017 and December 31, 2016, respectively,~~2018, the Company had ~~$119.0~~$242.0 million drawn, letters of credit issued in the amount of $25.1 million, and ~~$87.0~~$232.9 million of remaining borrowing capacity available under the New Credit Agreement. At December 31, 2017, the Company had $144.0 million drawn and letters of credit ~~totaling $11.0~~issued in the amount of $9.6 million ~~outstanding~~ under ~~its credit facilities with Capital One, National Association.~~the Prior Credit Facility.

AsUnder the terms of ~~September 30, 2017,~~the New Credit Agreement, the Company ~~had $95.0 million available for borrowing under the~~is required to maintain certain financial ratios and comply with certain financial covenants. The new Credit Agreement permits the Company to make certain restricted payments, such as purchasing shares of its stock, within certain parameters, provided the Company maintains compliance with ~~Capital One, National Association.~~

those financial ratios and covenants after giving effect to such restricted payments. The Company was in compliance with debt covenants at June 30, 2018.

6.7. Stockholder’s Equity

Equity Based Awards

~~The~~At the LHC Group, Inc. 2018 Annual Meeting of Stockholders held on June 7, 2018, the stockholders of the Company approved the adoption of the LHC Group, Inc. 2018 Incentive Plan (the "2018 Incentive Plan") to replace the Company's 2010 Long Term Incentive Plan. The 2018 Incentive Plan ~~(the “2010 Incentive Plan”) is~~will be administered by the Compensation Committee of the Company’s Board of Directors. AThe total number of ~~1,500,000~~ shares of the ~~Company’s~~Company's common stock ~~were~~originally reserved and ~~391,414 shares are currently~~ available for issuance pursuant to awards granted under the 2018 Incentive Plan was 2,000,000, plus an additional number of shares (not to exceed 300,000) underlying stock awards granted under the Company's 2010 Long-Term Incentive Plan (the "Prior Plan") that terminate, expire or forfeited. As of June 30, 2018, there were approximately 210,544 shares of our common stock subject to outstanding awards, and approximately 2,000,000 shares of our common stock reserved and available for future awards, under the 2018 Incentive Plan. A variety of discretionary awards for employees, officers, directors, and consultants are authorized under the ~~2010~~2018 Incentive Plan, including incentive or non-qualified ~~statutory~~ stock options and ~~nonvested stock.~~restricted stock, restricted stock units and performance-based awards. All awards must be evidenced by a written award certificate which will include the provisions specified by the Compensation Committee of the Board of Directors. The Compensation Committee determines the exercise price for ~~non-statutory~~ stock ~~options. The exercise price for any option~~options, which cannot be less than the fair market value of the Company’s common stock as of the date of grant.

Almost Family had Stock and Incentive Compensation Plans that provided for stock awards of the Company’s common stock to employees, non-employee directors or independent contractors. Almost Family issued restricted share and/or option awards to employees and non-employee directors. Under the change in control provisions of the Almost Family plans, all outstanding restricted stock, performance restricted stock, and options became non-forfeitable in conjunction with the Merger.

Each unvested restricted share award issued by Almost Family that was outstanding immediately prior to the Merger converted into a restricted stock award to acquire shares of the Company on the same terms and conditions rounded up or down to the nearest whole share, determined by multiplying the number of shares of Almost Family common stock subject to such restricted share award by the exchange ratio. Each stock option to purchase shares of Almost Family that was outstanding immediately prior to the Merger converted into an option to purchase shares of the Company on the same terms and conditions, (A) the number of shares of LHC common stock, rounded down to the nearest whole share, determined by multiplying (I) the total number of shares of Almost Family common stock by (II) the exchange ratio, and (B) at a per-share exercise price, rounded up to the nearest whole cent, equal to the quotient determined by dividing (I) the exercise price per share of Almost Family common stock by (II) the exchange ratio.

Share Based Compensation

Nonvested Stock

During the ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2018, the Company’s independent directors were granted ~~11,700~~13,600 nonvested shares of common stock under the Second Amended and Restated 2005 Non-Employee Directors Compensation Plan. The shares ~~were drawn from the 1,500,000 shares of common stock reserved for issuance under the 2010 Incentive Plan. The shares~~ vest 100% on the one year anniversary date. During the ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2018, four new directors were granted 14,000 nonvested shares of common stock under the Second Amended and Restated 2005 Non-Employee Directors Compensation Plan. The shares vest 33% at the grant date, then 33% each year on the anniversary date until the third year. The shares were drawn from the 2,300,000 shares of common stock reserved for issuance under the 2018 Incentive Plan. During the six months ended June 30, 2018, employees were granted ~~139,310~~213,105 nonvested shares of common stock pursuant to the 2010 Incentive Plan. The shares vest over a period of five years, conditioned on continued employment. The fair value of nonvested shares of common stock is determined based on the closing trading price of the Company’s common stock on the grant date. The weighted average grant date fair value of nonvested shares of common stock granted during the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 was ~~$48.52.~~$62.35.

The following table represents the nonvested stock activity for the ~~nine~~six months ended ~~September~~June 30, ~~2017:~~

2018:

Number of
shares

Weighted
average grant
date fair value
Nonvested shares outstanding as of December 31, 2016 574,711
$ 31.61
Granted 151,010
$ 48.52
Vested (191,463 ) $ 28.91
Forfeited (3,793 ) $ 39.30
Nonvested shares outstanding as of September 30, 2017 530,465
$ 37.35



	Restricted stock				Options
	Number of shares		Weighted average grant date fair value		Number of shares		Weighted average grant date fair value
Nonvested shares outstanding as of December 31, 2017	529,465		$	37.34	—		$	—
Granted	240,705		$	62.35	—		$	—
Acquired	—		$	—	270,710		$	36.48
Vested or exercised	(176,385	)	$	34.93	(10,727	)	$	29.08
Nonvested shares outstanding as of June 30, 2018	593,785		$	48.20	259,983		$	36.66

As of ~~September~~June 30, ~~2017,~~2018, there was ~~$14.9~~$23.4 million of total unrecognized compensation cost related to nonvested shares of common stock granted. That cost is expected to be recognized over the weighted average period of ~~3.13~~3.40 years. ~~The total fair value of shares of common stock vested during the nine months ended September 30, 2017 was $5.5 million.~~ The Company records compensation expense related to nonvested stock awards at the grant date for shares of common stock that are awarded fully vested, and over the vesting term on a straight line basis for shares of common stock that vest over time. The Company recorded ~~$4.5~~$3.9 million and ~~$3.5~~$3.1 million of compensation expense related to nonvested stock grants infor each of the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and ~~2016, respectively.~~2017.

Employee Stock Purchase Plan

In 2006, the Company adopted the Employee Stock Purchase Plan whereby eligible employees may purchase the Company’s common stock at 95% of the market price on the last day of the calendar quarter. There were 250,000 shares of common stock initially reserved for the plan. In 2013, the Company adopted the Amended and Restated Employee Stock Purchase Plan, which reserved an additional 250,000 shares of common stock to the plan.

The table below details the shares of common stock issued during ~~2017:~~2018:

Number of
shares

Per share
price
Shares available as of December 31, 2016 189,611

Shares issued during the three months ended March 31, 2017 5,891
$ 43.42
Shares issued during the three months ended June 30, 2017 4,152
$ 51.21
Shares issued during the three months ended September 30, 2017.......................................................... 4,775
$ 64.49
Shares available as of September 30, 2017 174,793



	Number of shares	Per share price
Shares available as of December 31, 2017	171,069
Shares issued during the three months ended March 31, 2018	5,534	$	58.19
Shares issued during the three months ended June 30, 2018	5,171	$	58.48
Shares available as of June 30, 2018	160,364

Treasury Stock

In conjunction with the vesting of the nonvested shares of common stock, recipients incur personal income tax obligations. The Company allows the recipients to turn in shares of common stock to satisfy minimum tax obligations. During the ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2018, the Company redeemed ~~61,502~~63,161 shares of common stock valued at ~~$3.1~~$3.9 million, related to

these tax obligations. In addition, the Company redeemed 5,485 shares of common stock valued at $0.2 million, related to the exercise of Almost Family options. Such shares are held as treasury stock and are available for reissuance by the Company.

Additionally, shares were submitted by employees in lieu of exercise price that would have otherwise been due on exercise of stock options, which shares are held in treasury stock and are available for reissuance by the Company.

7.8. Commitments and Contingencies

Contingencies

Regulatory Matters

The Company provides services in a highly regulated industry and is a party to various proceedings and regulatory and other governmental and internal audits and investigations in the ordinary course of business (including audits by Zone Program Integrity Contractors ("ZPICs") and Recovery Audit Contractors ("RACs") and investigations resulting from the Company's obligation to self-report suspected violations of law). Management cannot predict the ultimate outcome of any regulatory and other governmental and internal audits and investigations. While such audits and investigations are the subject of administrative appeals, the appeals process, even if successful, may take several years to resolve. The Department of Justice, CMS, or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company's ~~businesses in the future.~~businesses. These audits and investigations have caused and could potentially continue to cause delays in collections, ~~and~~ recoupments from governmental payors. Currently, the Company has recorded $16.9 million in other assets, which are from government payors ~~and~~related to the disputed finding of pending appeals of ZPIC audits. Additionally, these audits may subject the Company to sanctions, damages, extrapolation of damage findings, additional recoupments, fines, and other penalties (some of which may not be covered by insurance), which may, either individually or in the aggregate, have a material adverse effect on the Company's business and financial condition.

Merger Related Litigation

On January 18, 2018, Jordan Rosenblatt, a purported shareholder of Almost Family filed a complaint for violations of the Securities Exchange Act of 1934 in the United States District Court for the Western District of Kentucky, styled Rosenblatt v. Almost Family, Inc., et al., Case No. 3:18-cv-40-TBR (the “Rosenblatt Action”). The Rosenblatt Action was filed against the Company, Almost Family, Almost Family’s board of directors, and Hammer Merger Sub. The complaint in the Rosenblatt Action (“Rosenblatt Complaint”) asserts, among other things, that the Form S-4 Registration Statement (“Registration Statement”) filed on December 21, 2017 in connection with the Merger contained false and misleading statements with respect to the Merger. The Rosenblatt Action sought, among other things, an injunction enjoining the Merger from closing and an award of attorneys’ fees and costs.

In addition to the Rosenblatt Action, two additional complaints were filed against Almost Family in the United States District Court for the District of Delaware (the "Delaware Actions") alleging similar violations as the Rosenblatt Action. These Delaware Actions also sought, among other things, an injunction to enjoin both the vote of the Almost Family stockholders with respect to the Merger and the closing of the Merger, monetary damages and an award of attorneys’ fees and costs from Almost Family.

On February 22, 2018, plaintiffs in the Delaware Actions moved for a preliminary injunction to enjoin the merger of Almost Family and Merger Sub. Then, on March 2, 2018, the Delaware Actions were transferred to the United States District Court for the Western District of Kentucky. Shortly thereafter, on March 12, 2018, Almost Family, LHC and Merger Sub opposed the plaintiffs’ motion for a preliminary injunction, and the court heard oral argument on the plaintiffs’ motion for a preliminary injunction on March 19, 2018. On March 22, 2018, the court denied plaintiffs’ motion for preliminary injunction. The next day, on March 23, 2018, one of the plaintiffs in the Delaware Actions moved to consolidate the Delaware Actions with the Rosenblatt Action and for the appointment of a lead plaintiff, and that motion is pending before the court.

We believe that the claims asserted in these lawsuits are entirely without merit and intend to defend these lawsuits vigorously.

Other Litigation

We are involved in various other legal proceedings arising in the ordinary course of business. Although the results of litigation cannot be predicted with certainty, ~~management believes~~we believe the outcome of pending litigation will not have a material adverse effect, after considering the effect of ~~the Company’s~~our insurance coverage, on ~~the Company’s interim~~our consolidated financial information.

Joint Venture Buy/Sell Provisions

Most of the Company’s joint ventures include a buy/sell option that grants to the Company and its joint venture partners the right to require the other joint venture party to either purchase all of the exercising member’s membership interests or sell to the exercising member all of the non-exercising member’s membership interest, at the non-exercising member’s option, within 30 days of the receipt of notice of the exercise of the buy/sell option. In some instances, the purchase price is based on a multiple of the historical or future earnings before income taxes and depreciation and amortization of the equity joint venture at the time the buy/sell option is exercised. In other instances, the buy/sell purchase price will be negotiated by the partners and subject to a fair market valuation process. The Company has not received notice from any joint venture partners of their intent to exercise the terms of the buy/sell agreement nor has the Company notified any joint venture partners of its intent to exercise the terms of the buy/sell agreement.

Compliance

The laws and regulations governing the Company’s operations, along with the terms of participation in various government programs, regulate how the Company does business, the services offered and its interactions with patients and the public. These laws and regulations, and their interpretations, are subject to frequent change. Changes in existing laws or regulations, or their interpretations, or the enactment of new laws or regulations could materially and adversely affect the Company’s operations and financial condition.

The Company is subject to various routine and non-routine governmental reviews, audits and investigations. In recent years, federal and state civil and criminal enforcement agencies have heightened and coordinated their oversight efforts related to the health care industry, including referral practices, cost reporting, billing practices, joint ventures and other financial relationships among health care providers. Violation of the laws governing the Company’s operations, or changes in the interpretation of those laws, could result in the imposition of fines, civil or criminal penalties and/or termination of the Company’s rights to participate in federal and state-sponsored programs and suspension or revocation of the Company’s licenses. The Company believes that it is in material compliance with all applicable laws and regulations.

8.9. Noncontrolling interest

~~Noncontrolling Interest-Redeemable~~

~~A majority~~The Company classifies noncontrolling interests of its joint venture parties based upon a review of the legal provisions governing the redemption of such interests. In each of the Company’s joint ventures, those provisions are embodied within the joint venture’s operating agreement. For joint ventures with operating agreement provisions that establish an obligation for the Company to purchase the third party partners’ noncontrolling interests other than as a result of events that lead to a liquidation of the joint venture, such noncontrolling interests are classified as redeemable noncontrolling interests in temporary equity. For joint ventures with operating agreement provisions that establish an obligation that the Company purchase the third party partners’ noncontrolling interests, but which obligation is triggered by events that lead to a liquidation of the joint venture, such noncontrolling interests are classified as nonredeemable noncontrolling interests in permanent equity. Additionally, for joint ventures with operating agreement provisions that do not establish an obligation for the Company to purchase the third party partners’ noncontrolling interests (e.g., where the Company has the option, but not the obligation, to purchase the third party partners’ noncontrolling interests), such noncontrolling interests are classified as nonredeemable noncontrolling interests in permanent equity.

The Company’s equity joint ~~venture agreements include a provision~~ventures that ~~requires~~are classified as redeemable noncontrolling interests are subject to operating agreement provisions that require the Company to purchase the noncontrolling partner’s interest upon the occurrence of certain triggering events, ~~such~~which are defined as ~~death or~~the bankruptcy of the partner or the partner’s exclusion from the Medicare or Medicaid programs. These triggering events and the related repurchase provisions are specific to each ~~individual equity joint venture; if the repurchase provision is triggered in any one~~redeemable equity joint venture, since the ~~remaining~~triggering of a repurchase obligation for any one redeemable noncontrolling interest in an equity joint ~~ventures would~~venture does not ~~be impacted.~~necessarily impact any of the other redeemable noncontrolling interests in other equity joint ventures. Upon the occurrence of a triggering event requiring the purchase of a redeemable noncontrolling interest, the Company would be required to purchase the noncontrolling partner’s interest ~~at either the fair value or the book value at the time of purchase, as stated~~based upon a valuation methodology set forth in the applicable joint venture agreement. ~~The~~

Redeemable noncontrolling interests and nonredeemable noncontrolling interests are initially recorded at their fair value as of the closing date of the transaction establishing the joint venture. Such fair values are determined using various accepted valuation methods, including the income approach, the market approach, the cost approach, and a combination of one or more of these approaches. A number of facts and circumstances concerning the operation of the joint venture are evaluated for each transaction, including (but not limited to) the ability to choose management, control over acquiring or liquidating assets, and controlling the joint venture’s strategy and direction, in order to determine the fair value of the noncontrolling interest.

Based upon the Company’s evaluation of the redemption provisions concerning redeemable noncontrolling interests as of June 30, 2018, the Company ~~has never been required~~determined in accordance with authoritative accounting guidance that it was not probable that an

event otherwise requiring redemption of any redeemable noncontrolling interest would occur (i.e., the date for such event was not set or such event is not certain to ~~purchase~~occur). Therefore, none of the redeemable noncontrolling interests were identified as mandatorily redeemable interests at such times, and the Company did not record any values in respect of any mandatorily redeemable interests.

Subsequent to the closing date of the transaction establishing the joint venture, the Company records adjustments to the carrying amounts of noncontrolling interests during each reporting period to reflect (a) comprehensive income (loss) attributed to each noncontrolling interest, which is calculated by multiplying the noncontrolling interest percentage by the comprehensive income (loss) of the joint venture’s operations, (b) dividends paid to the noncontrolling interest partner, and (c) any ~~of its equity~~other transactions that increase or decrease the Company’s ownership interest in each joint venture, ~~partners, and~~as a result of which the Company ~~believes~~retains its controlling interest. If the ~~likelihood~~Company determines that, based upon its analysis as of the end of each reporting period in accordance with authoritative accounting guidance, that it is not probable that an event would occur to otherwise require the redemption of a ~~triggering event occurring is remote. According to authoritative guidance,~~ redeemable noncontrolling ~~interests must be~~interest (i.e., the date for such event is not set or such event is not certain to occur), then the Company does not adjust the recorded amount of such redeemable noncontrolling interest.

The carrying amount of each redeemable equity instrument presented in temporary equity for the six months ended June 30, 2018 is not less than the initial amount reported ~~outside of permanent equity on the consolidated balance sheet in instances where there is a repurchase provision with a triggering event that is outside the control of the Company.~~

for each instrument. The following table summarizes the activity of noncontrolling interest-redeemable for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 (amounts in thousands):

Balance as of December 31, 2016 $ 12,567
Net income attributable to noncontrolling interest-redeemable 7,649
Noncontrolling interest-redeemable distributions (6,933 )
Sale of noncontrolling interest-redeemable (77 )
Balance as of September 30, 2017 $ 13,206

~~9. Allowance for Uncollectible Accounts~~

~~The following table summarizes the activity in the allowance for uncollectible accounts for the nine months ended September 30, 2017 (amounts in thousands):~~

Balance as of December 31, 2016 $ 29,036
Additions 8,238
Deductions (11,185 )
Balance as of September 30, 2017 $ 26,089

The allowance for uncollectible accounts declined to 15.2% from 18.9% of patient accounts receivable over the nine months ended September 30, 2017. This was due to a reduction in provision of bad debts due to more timely cash collections and an increase in amounts collected. Patient accounts receivable over 180 days decreased 17% during the nine months ended September 30, 2017 due to the Company's continued process improvements. The maturity of the Company's back office and field operations, the use of the point-of-care platform, and the use of other technology advancements in reporting and analytics were the drivers of improved collections.



Balance as of December 31, 2017	$	13,393
Net income attributable to noncontrolling interest-redeemable	4,855
Noncontrolling interest-redeemable distributions	(4,644		)
Acquired noncontrolling interest-redeemable	3,428
Balance as of June 30, 2018	$	17,032

10. Fair Value of Financial Instruments

The carrying amounts of the Company’s cash, receivables, accounts payable and accrued liabilities approximate their fair values because of their short maturity. The estimated fair value of intangible assets acquired was calculated using level 3 inputs

based on the present value of anticipated future benefits. For the ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2018, the carrying value of the Company’s long-term debt approximates fair value as the interest rates approximate current rates.

11. Segment Information

~~The Company’s reportable~~In the second quarter of 2018, in recognition of the changes to the Company's business segments ~~consist~~resulting from the addition of Almost Family and its subsidiaries through the Merger, the Company redefined its reporting segments to include (1) home health services, (2) hospice services, (3) home and community-based services, formerly referred to by the Company as community-based services, (4) facility-based services and (5) healthcare innovations (“HCI”). In management’s opinion, this approach provides investors clarity and best aligns with the Company’s internal decision-making processes as viewed by the chief operating decision maker. Reportable segments have been identified based upon how management has organized the business by services provided to customers and how the chief operating decision maker manages the business and allocates resources, consistent with the criteria in ASC 280, Segment Reporting.

The home health segment provides skilled medical services in patients’ homes largely to enable recipients to reduce or avoid periods of hospitalization and/or nursing home care. Approximately 72.9% of the home health services segment revenues were generated from the Medicare program, while the balance is generated from Medicaid and private insurance programs.

The hospice segment services are largely provided in patients’ homes and generally require specialized hospice nursing skills. Hospice services segment revenues are generated on a per diem basis and are primarily from Medicare, which account for approximately 91.1% of hospice services segment revenues.

The home and community-based segment services includes traditional home and community-based services (generally provided by paraprofessional staff such as home health aides) which are generally of a custodial rather than skilled nature. Home and community-based services segment revenues are generated on an hourly basis and are primarily from Medicaid, which account for approximately 24.7% of home and community-based services segment revenues.

The facility-based ~~services.~~ segment services includes services provided through LTACHs, a family health center, two pharmacies, a rural health clinic, and two physical therapy clinics. The facility-based services segment is reimbursed primarily by Medicare under the LTACH prospective payment system, which accounts for approximately 58.7% of facility-based services segment revenue.

The HCI segment combines reporting on the Company’s developmental activities outside its other business segments. The HCI segment includes (a) Imperium Health Management, LLC, an ACO enablement company, (b) Long Term Solutions, Inc., an in-home assessment company serving the long-term care insurance industry, and certain assets operated by Advanced Care House Calls, which provides primary medical care for home-bound or home-limited patients with chronic and acute illnesses who have difficulty traveling to a doctor’s office, (c) Ingenios Health Co., a Nurse-Practitioner-oriented and mobile technology-enabled health risk assessment company primarily serving managed care organizations, and (d) an investment in Care Journey (formerly NavHealth, Inc.), a population-health analytics company. These activities are intended ultimately, whether directly or indirectly, to benefit the Company’s patients and payors through the enhanced provision of services in the Company’s other segments. The activities all share a common goal of improving patient experiences and quality outcomes, while lowering costs. They include, but are not limited to, items such as: technology, information, population health management, risk-sharing, care-coordination and transitions, clinical advancements, enhanced patient engagement and informed clinical decision and technology enabled in-home clinical assessments.

The accounting policies of the segments are the same as those described in the summary of significant accounting policies, as described in Note 2 of the Notes to Condensed Consolidated Financial ~~Statements.~~Statements, including the adoption of ASU 2014-09.

The following tables summarize the Company’s segment information for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and ~~2016~~2017 (amounts in thousands):


	Three Months Ended September 30, 2017															Three Months Ended June 30, 2018
	Home health services			Hospice services			Community-based services			Facility-based services			Total			Home health services			Hospice services			Home and community-based services			Facility-based services			HCI			Total
Net service revenue	$	198,978		$	41,291		12,146			$	20,457		$	272,872		$	360,276		$	50,554		52,753			$	28,304		$	10,137		$	502,024
Cost of service revenue	123,204			27,441			8,971			13,240			172,856			230,293			33,493			40,349			19,307			6,204			329,646
Provision for bad debts	2,661			234			30			269			3,194
General and administrative expenses	55,980			11,263			2,387			6,039			75,669			99,162			14,613			11,777			11,088			4,710			141,350
(Gain) loss on disposal of assets	20			13			—			(210		)	(177		)
Operating income	17,113			2,340			758			1,119			21,330
Operating income (loss)																30,821			2,448			627			(2,091		)	(777		)	31,028
Interest expense	(746		)	(149		)	(50		)	(50		)	(995		)	(2,256		)	(473		)	(158		)	(159		)	(156		)	(3,202		)
Income before income taxes and noncontrolling interest	16,367			2,191			708			1,069			20,335
Income (loss) before income taxes and noncontrolling interest																28,565			1,975			469			(2,250		)	(933		)	27,826
Income tax expense	5,703			931			338			473			7,445			7,091			483			139			(313		)	(230		)	7,170
Net income	10,664			1,260			370			596			12,890
Net income (loss)																21,474			1,492			330			(1,937		)	(703		)	20,656
Less net income (loss) attributable to noncontrolling interests	1,759			273			(21		)	(27		)	1,984			3,810			412			(90		)	(207		)	(66		)	3,859
Net income attributable to LHC Group, Inc.’s common stockholders	$	8,905		$	987		$	391		$	623		$	10,906
Net income (loss) attributable to LHC Group, Inc.’s common stockholders																$	17,664		$	1,080		$	420		$	(1,730	)	$	(637	)	$	16,797
Total assets	$	515,562		$	156,296		$	44,621		$	48,574		$	765,053		$	1,306,773		$	189,447		$	255,456		$	66,665		$	63,329		$	1,881,670


																Three Months Ended June 30, 2017
	Three Months Ended September 30, 2016															(as adjusted)
	Home health services			Hospice services			Community-based services			Facility-based services			Total			Home health services			Hospice services			Home and community-based services			Facility-based services			HCI		Total
Net service revenue	$	167,529		$	35,322		$	11,793		$	16,153		$	230,797		$	192,409		$	37,851		$	10,746		$	16,529		$	—	$	257,535
Cost of service revenue	100,057			21,243			9,100			10,432			140,832			117,606			24,473			7,986			11,093			—		161,158
Provision for bad debts	2,049			797			190			239			3,275
General and administrative expenses	50,293			9,491			2,263			4,952			66,999			55,268			10,743			2,261			5,280			—		73,552
Loss on disposal of assets	20			5			—			117			142
Operating income	15,110			3,786			240			413			19,549			19,535			2,635			499			156			—		22,825
Interest expense	(612		)	(90		)	(41		)	(73		)	(816		)	(630		)	(126		)	(42		)	(42		)	—		(840		)
Income before income taxes and noncontrolling interest	14,498			3,696			199			340			18,733			18,905			2,509			457			114			—		21,985
Income tax expense	5,133			1,275			83			71			6,562			6,757			849			180			6			—		7,792
Net income	9,365			2,421			116			269			12,171			12,148			1,660			277			108			—		14,193
Less net income attributable to noncontrolling interests	1,853			553			—			149			2,555			2,266			480			5			138			—		2,889
Net income attributable to LHC Group, Inc.’s common stockholders	$	7,512		$	1,868		$	116		$	120		$	9,616
Net income (loss) attributable to LHC Group, Inc.’s common stockholders																$	9,882		$	1,180		$	272		$	(30	)	$	—	$	11,304
Total assets	$	425,923		$	119,906		$	33,549		$	34,075		$	613,453		$	466,308		$	138,519		$	33,292		$	34,547		$	—	$	672,666


	Nine Months Ended September 30, 2017															Six Months Ended June 30, 2018
	Home health services			Hospice services			Community-based services			Facility-based services			Total			Home health services			Hospice services			Home and community-based services			Facility-based services			HCI			Total
Net service revenue	$	575,180		$	116,249		$	33,807		$	54,464		$	779,700		$	564,463		$	93,180		66,844			$	58,454		$	10,137		$	793,078
Cost of service revenue	352,896			75,187			24,905			35,396			488,384			360,453			61,512			51,139			38,956			6,204			518,264
Provision for bad debts	5,796			1,393			404			645			8,238
General and administrative expenses	165,153			32,404			6,957			16,563			221,077			165,452			27,910			15,075			20,234			4,710			233,381
(Gain) loss on disposal of assets	39			21			—			(83		)	(23		)
Operating income	51,296			7,244			1,541			1,943			62,024			38,558			3,758			630			(736		)	(777		)	41,433
Interest expense	(1,961		)	(393		)	(130		)	(131		)	(2,615		)	(3,343		)	(690		)	(230		)	(232		)	(157		)	(4,652		)
Income before income taxes and noncontrolling interest	49,335			6,851			1,411			1,812			59,409
Income (loss) before income taxes and noncontrolling interest																35,215			3,068			400			(968		)	(934		)	36,781
Income tax expense	16,712			2,439			602			657			20,410			7,813			594			124			(154		)	(230		)	8,147
Net income	32,623			4,412			809			1,155			38,999
Net income (loss)																27,402			2,474			276			(814		)	(704		)	28,634
Less net income (loss) attributable to noncontrolling interests	6,053			1,038			(7		)	237			7,321			6,047			829			(70		)	102			(66		)	6,842
Net income attributable to LHC Group, Inc.’s common stockholders	$	26,570		$	3,374		$	816		$	918		$	31,678
Net income (loss) attributable to LHC Group, Inc.’s common stockholders																$	21,355		$	1,645		$	346		$	(916	)	$	(638	)	$	21,792


																Six Months Ended June 30, 2017
	Nine Months Ended September 30, 2016															(as adjusted)
	Home health services			Hospice services			Community-based services			Facility-based services			Total			Home health services			Hospice services			Home and community-based services			Facility-based services			HCI		Total
Net service revenue	$	492,090		$	100,051		$	32,823		$	54,416		$	679,380		$	373,067		$	73,799		$	21,287		$	33,631		$	—	$	501,784
Cost of service revenue	294,359			61,836			24,656			32,710			413,561			229,692			47,746			15,934			22,156			—		315,528
Provision for bad debts	8,122			2,364			488			684			11,658
General and administrative expenses	150,948			27,787			6,557			16,004			201,296			109,190			21,149			4,572			10,652			—		145,563
Loss on disposal of assets	811			329			46			203			1,389
Operating income	37,850			7,735			1,076			4,815			51,476			34,185			4,904			781			823			—		40,693
Interest expense	(1,640		)	(232		)	(106		)	(189		)	(2,167		)	(1,215		)	(243		)	(81		)	(81		)	—		(1,620		)
Income before income taxes and noncontrolling interest	36,210			7,503			970			4,626			49,309			32,970			4,661			700			742			—		39,073
Income tax expense	11,026			2,484			413			1,577			15,500			11,010			1,508			263			184			—		12,965
Net income	25,184			5,019			557			3,049			33,809			21,960			3,153			437			558			—		26,108
Less net income (loss) attributable to noncontrolling interests	5,002			1,368			(57		)	730			7,043
Less net income attributable to noncontrolling interests																4,294			766			13			264			—		5,337
Net income attributable to LHC Group, Inc.’s common stockholders	$	20,182		$	3,651		$	614		$	2,319		$	26,766		$	17,666		$	2,387		$	424		$	294		$	—	$	20,771

12. Income Taxes

On December 22, 2017, the U.S. enacted significant changes to U.S. tax law following the passage and signing of “Tax Cuts and Jobs Act” or the “TCJA”. The TCJA is complex and significantly changes the U.S. corporate income tax system by, among other things, reducing the Federal corporate income tax rate from 35% to 21%. The effective tax rate for the six months ended June 30, 2018 and 2017 benefited from $0.9 million and $1.1 million, respectively, of excess tax benefits associated with stock-based compensation arrangements, which was offset by the effect of capitalized transaction costs related to the Merger during the six months ended June 30, 2018 of $0.9 million.

US GAAP prescribes a recognition threshold and measurement attribute for the accounting and financial statement disclosure of tax positions taken or expected to be taken in a tax return. The evaluation of a tax position is a two-step process. The first step requires the Company to determine whether it is more likely than not that a tax position will be sustained upon examination based on the technical merits of the position. The second step requires the Company to recognize in the financial statements each tax position that meets the more likely than not criteria, measured at the amount of benefit that has a greater than 50% likelihood of being realized. The Company’s unrecognized tax benefits would affect the tax rate, if recognized. The Company includes the full amount of unrecognized tax benefits in other noncurrent liabilities in the consolidated balance sheets. The Company anticipates it is reasonably possible an increase or decrease in the amount of unrecognized tax benefits could be made in the next twelve months. However, the Company does not presently anticipate that any increase or decrease in unrecognized tax benefits will be material to the consolidated financial statements. The amounts recognized as of June 30, 2018 was $3.9 million.

13. Subsequent Events

Management has evaluated all events and transactions that occurred after June 30, 2018. During this period, the Company had no material subsequent events requiring recognition in the consolidated financial statements, except as noted below:

On July 1, 2018, the Company purchased the remaining redeemable noncontrolling interest for one of its joint ventures for $7.0 million, with a short-term earn out provision, which could increase the purchase price to a maximum of $10.0 million.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS

This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains certain statements and information that may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements relate to future plans and strategies, anticipated events or trends, future financial performance, and expectations and beliefs concerning matters that are not historical facts or that necessarily depend upon future events. The words “may,” “should,” “could,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “potential,” and similar expressions are intended to identify forward-looking statements. Specifically, this report contains, among others, forward-looking statements about:

our expectations regarding financial condition or results of operations for periods after ~~September~~June 30, ~~2017;~~2018;

our critical accounting policies;

our business strategies and our ability to grow our business;

our participation in the Medicare and Medicaid programs;

the reimbursement levels of Medicare and other third-party payors;

the prompt receipt of payments from Medicare and other third-party payors;

our future sources of and needs for liquidity and capital resources;

the effect of any regulatory changes ~~under the new presidential administration;~~or anticipated regulatory changes;

the effect of any changes in market rates on our operations and cash flows;

our ability to obtain financing;

our ability to make payments as they become due;

the outcomes of various routine and non-routine governmental reviews, audits and investigations;

our expansion strategy, the successful integration of recent acquisitions and, if necessary, the ability to relocate or restructure our current facilities;

the value of our proprietary technology;

the impact of legal proceedings;

our insurance coverage;

our competitors and our competitive advantages;

our ability to attract and retain valuable employees;

the price of our stock;

our compliance with environmental, health and safety laws and regulations;

our compliance with health care laws and regulations;

our compliance with ~~SEC~~Securities and Exchange Commission laws and regulations and Sarbanes-Oxley requirements;

the impact of federal and state government regulation on our business; ~~and~~

the impact of changes in future interpretations of fraud, anti-kickback, or other ~~laws.~~laws;

the integration of the Almost Family and the Company's business;

the cost savings, synergies, growth and other benefits from the Almost Family Merger, which may not be fully realized or may take longer to realize than expected; and

costs associated with the integration of the businesses of the Company and Almost Family, which could be higher than anticipated.

The forward-looking statements included in this report reflect our current views about future events, are based on assumptions, and are subject to known and unknown risks and uncertainties. Many important factors could cause actual results or achievements to differ materially from any future results or achievements expressed in or implied by our forward-looking statements. Many of the factors that will determine future events or achievements are beyond our ability to control or predict. Important factors that could cause actual results or achievements to differ materially from the results or achievements reflected in our forward-looking statements include, among other things, the factors discussed in the Part II, Item 1A. “Risk Factors,” included in this report and in our other filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, ~~2016~~2017 (the ~~“2016~~“2017 Form 10-K”), as updated by our subsequent filings with the SEC. This report should be read in conjunction with the ~~2016~~2017 Form 10-K, and all of our other filings made with the SEC through the date of this report, including quarterly reports on Form 10-Q and current reports on Form 8-K.

You should read this report, the information incorporated by reference into this report, and the documents filed as exhibits to this report completely and with the understanding that our actual future results or achievements may differ materially from what we expect or anticipate.

The forward-looking statements contained in this report reflect our views and assumptions only as of the date this report is filed with the SEC. Except as required by law, we assume no responsibility for updating any forward-looking statements.

We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Unless the context otherwise requires, “we,” “us,” “our,” and the “Company” refer to LHC Group, Inc. and its consolidated ~~subsidiaries.~~subsidiaries (including, as a result of the Merger, those owned and operated by Almost Family).

OVERVIEW

General

We provide quality, cost-effective post-acute health care services to our patients. As of ~~September~~June 30, ~~2017,~~2018, we have ~~449~~777 service providers in ~~27 states.~~37 states within the continental United States. Our services are classified into ~~four~~five segments: (1) home health services, (2) hospice services, (3) home and community-based services, ~~and~~ (4) facility-based services offered through our long-term acute care hospitals (“LTACHs”). and (5) healthcare innovations services. We intend to increase the number of service providers within each of our ~~four~~ segments that we operate through continued acquisitions, joint ventures, and organic development.

~~Through our~~Our home health ~~services segment, we~~service locations offer a wide range of services, including skilled nursing, medically-oriented social services, and physical, occupational, and speech therapy. As of ~~September~~June 30, ~~2017,~~2018, we operated ~~324~~568 home health services locations, of which ~~166~~313 are wholly-owned, ~~152~~243 are majority-owned through equity joint ventures, three are under license lease arrangements, and the operations of the remaining ~~three~~nine locations are only managed by us.

~~Through our hospice services segment, we~~Our hospices provide end-of-life care to patients with terminal illnesses through interdisciplinary teams of physicians, nurses, home health aides, counselors, and volunteers. We offer a wide range of services, including pain and symptom management, emotional and spiritual support, inpatient and respite care, homemaker services, and counseling. As of ~~September~~June 30, ~~2017,~~2018, we operated 92106 hospice locations, of which 4660 are wholly-owned, 44 are majority-owned through equity joint ventures, and two are under license lease arrangements.

Through our home and community-based services segment, services are performed by skilled nursing and paraprofessional personnel, and include assistance with activities of daily living to the elderly, chronically ill, and disabled patients. As of ~~September~~June 30, ~~2017,~~2018, we operated 1280 home and community-based services locations: 1071 are wholly-owned and ~~two~~nine are majority-owned through an equity joint venture.

We provide facility-based services principally through our LTACHs. As of ~~September~~June 30, ~~2017,~~2018, we operated 11 LTACHs with 1512 locations, of which all but one are located within host hospitals. Of these facility-based services locations, ~~three~~two are wholly-owned, 11nine are majority-owned through equity joint ventures, and one location is managed by us. We also wholly-own and operate a family health center, two pharmacies, a rural health clinic, and ~~two~~three physical therapy clinics.

Our HCI segment reports on our developmental activities outside its other business segments. The HCI segment includes (a) Imperium Health Management, LLC, an ACO enablement company, (b) Long Term Solutions, Inc., an in-home assessment company serving the long-term care insurance industry, Long Term Solutions, Inc., and certain assets operated by Advanced Care House Calls, which provides primary medical care for home-bound or home-limited patients with chronic and acute illnesses who have difficulty traveling to a doctor’s office, (c) Ingenios Health Co., a Nurse-Practitioner-oriented and mobile technology-enabled health risk assessment company primarily serving managed care organizations, and (d) an investment in Care Journey (formerly NavHealth, Inc.), a population-health analytics company. These activities are intended ultimately, whether directly or indirectly, to benefit our patients and/or payors through the enhanced provision of services in our other segments. The activities all share a common goal of improving patient experiences and quality outcomes, while lowering costs. They include, but are not limited to, items such as: technology, information, population health management, risk-sharing, care-coordination and transitions, clinical advancements, enhanced patient engagement and informed clinical decision and technology enabled in-home clinical assessments. We have four HCI locations, of which three are wholly-owned, and one is majority-owned through an equity joint venture.

The Joint Commission is a nationwide commission that establishes standards relating to the physical plant, administration, quality of patient care, and operation of medical staffs of health care organizations. Currently, Joint Commission accreditation of home nursing and hospice agencies is voluntary. However, some managed care organizations use Joint Commission accreditation as a credentialing standard for regional and state contracts. As of ~~September~~June 30, ~~2017,~~2018, the Joint Commission had accredited ~~299~~358 of our ~~324~~568 home health services locations and 6164 of our 92106 hospice agencies. Those not yet accredited are working towards achieving this accreditation. As we acquire companies, we apply for accreditation 12 to 18 months after completing the acquisition.

The percentage of net service revenue contributed from each reporting segment for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and ~~2016~~2017 was as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended June 30,				Six Months Ended June 30,
Reporting segment	2017		2016		2017		2016		2018		2017		2018		2017
Home health services	72.9	%	72.6	%	73.8	%	72.5	%	71.8	%	74.5	%	71.2	%	74.2	%
Hospice services	15.1		15.3		14.9		14.7		10.1		14.8		11.7		14.8
Community-based services	4.5		5.1		4.3		4.8
Home and community-based services									10.5		4.2		8.4		4.3
Facility-based services	7.5		7.0		7.0		8.0		5.6		6.5		7.4		6.7
Healthcare innovations services									2.0		—		1.3		—
	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%

Recent Developments

The reader is encouraged to review our detailed discussion of health care legislation and Medicare regulations in the similarly titled section in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” along with the discussions in Part I, Item 1, “Business; Government Regulation” and in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 30, 2017, as supplemented in Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.

Home Health Services

On ~~April 14, 2015, legislation was passed which limits any increase in home health payments to 1% for fiscal year~~July 2, 2018, ~~and extended the 3% rural home health safeguard for two years through December 31, 2017.~~

~~On October 31, 2016,~~ CMS released ~~a Final Rule (effective January 1, 2017)~~the proposed rule regarding payment rates for home health services provided during calendar year 2017. The national, standardized 60-day episode payment rate increased to $2,989.97 for 2017. The rural rate is $3,079.67. The Final Rule implements the final year of the four year phase-in of the rebasing adjustments to the national, standardized 60-day episode payment rate and the decrease of 0.97% to account for nominal case-mix growth between calendar year 2012 and calendar year 2014, which was not accounted for in the rebasing adjustments finalized in calendar year 2014. The Final Rule also contains minor adjustments to the Home Health Value-Based Purchasing ("HHVBP") program and to the home health quality reporting program. CMS estimates the overall economic impact of the proposed rule's policy changes and payment rate update is an estimated aggregate decrease of 0.7% in payments to home health agencies, which decrease will vary based on each agency's wage index and patient mix weight.

In addition, CMS finalized its proposal to implement a HHVBP program that is intended to incentivize the delivery of high-quality patient care. The HHVBP program would withhold 3% to 8% of Medicare payments, which would be redistributed to participating home health agencies depending on their performance relative to specified measures. The HHVBP would apply

~~to all home health agencies in Arizona, Florida, Iowa, Massachusetts, Maryland, Nebraska, North Carolina, Tennessee, and Washington, effective January 1, 2018.~~

~~On November 1, 2017, CMS released the Final Rule (effective January 1, 2018) regarding payment rates for home health services provided during calendar year 2018.~~2019. The national, standardized 60-day episode payment rate will increase to ~~$3,039.64~~$3,151.22 in ~~2018.~~2019. The ~~Final Rule~~proposed rule estimates an impact of ~~0.5% reduction~~2.1% increase in payments due to the ~~expiration~~policy changes proposed in the rule. The rule implements a modified rural safeguard payment varying between 1.5% and 4.0% beginning in 2019 as prescribed by the Bipartisan Budget Act of 2018. The proposed rule also makes policy changes to the ~~rural add-on provision, a 1%~~ home health ~~payment update percentage, and 0.97% adjustment for case mix (the third year of a three year adjustment). CMS also estimates a reduction in regulatory~~quality reporting ~~due to~~program, the ~~removal of a number of quality measures and OASIS items. CMS estimates the overall economic impact of the Final Rule's changes and payment rate update is an estimated decrease of 0.4% in payments to~~ home health ~~agencies.~~value based purchasing demonstration, the home health high cost outlier policy, and simplifies certification and recertification requirements. In addition, effective January 1, 2020, CMS ~~decided not~~is proposing to ~~finalize its rule on~~implement the Patient Driven Groupings Model ("PDGM"), which is a modification of the Home Health Groupings Model ("HHGM") asthat was published in the 2018 proposed

rule but ~~instead~~which was not finalized. The PDGM will ~~take additional time to further engage with stakeholders to move towards a system that shifts the focus from volume of services~~shift home health payments to a ~~more patient-centered model.~~30-day payment period for which the national standardized rate would be set in the 2019 proposed rule.

~~Hospice Services~~Medicare Accountable Care Organizations (ACOs)

~~On July 29, 2016, CMS issued a Final Rule updating Medicare payment rates and the wage index for hospices for fiscal year 2017, which resulted in a 2.1% increase in payment rates.~~ The ~~2.1% increase is based on 2.7% inpatient hospital market basket update, reduced by a 0.3% productivity adjustment, and a 0.3% adjustment set by the Patient Protection and~~ Affordable Care Act ~~("PPACA"~~established ACOs as a tool to improve quality and lower costs through increased care coordination in the Medicare fee-for-service (“FFS”). program, also known as “Original Medicare.” The ~~hospice cap amount for the 2017 hospice cap year will be $28,404.99. The following table shows the hospice~~ Medicare ~~payment rates for fiscal year 2017, which began on October 1, 2016 and ended September 30, 2017:~~

Description Rate per patient day
Routine Home Care days 1-60 $ 190.55
Routine Home Care days 60+ $ 149.82
Continuous Home Care $ 964.63
Full Rate = 24 hours of care
$40.19 = hourly rate
Inpatient Respite Care $ 170.97
General Inpatient Care $ 734.94

On August 1, 2017, CMS issued a Final Rule updating Medicare payment rates and the wage index for hospices for fiscal year 2018. The result will be in a 1.0% increase in payment rates due to the provisions of Section 411 (d)FFS program covers approximately 70% of the Medicare ~~Access~~recipients or approximately 36 million eligible Medicare beneficiaries. ACOs are typically formed as legal entities by groups of doctors and ~~CHIP Reauthorization Act~~other healthcare providers who endeavor to work together to provide high quality services and care for their patients through three-year contracts with CMS. Provider and beneficiary participation in an ACO is purely voluntary and Medicare beneficiaries retain their current ability to seek treatment from any provider they wish. Beneficiaries are assigned to ACOs using an “attribution” model based on a plurality of ~~2015 (Pub. L. 114-10) ("MACRA"~~services provided by the primary care physician. Beneficiaries retain the right to use any doctor or hospital who accepts Medicare, at any time.

CMS established the Medicare Shared Savings Program (“MSSP”). to facilitate coordination and cooperation among providers to improve the quality of care for Medicare FFS beneficiaries and to reduce costs. Eligible providers, hospitals, and suppliers may participate in the MSSP by creating, participating in or contracting with an ACO. The ~~hospice cap~~MSSP is designed to improve beneficiary outcomes and increase value of care by (1) promoting accountability for the care of Medicare FFS beneficiaries, (2) requiring coordinated care for all services provided under Medicare FFS, and (3) encouraging investment in infrastructure and redesigned care processes. The MSSP will reward ACOs that provide healthcare services at a cost for the ACO’s patients during a relevant measurement year that is below the ACO’s benchmark costs established by CMS, while also meeting performance standards on quality of care. Under the final MSSP rules, Medicare is to reimburse individual providers and suppliers for specific items and services as Medicare currently does under the FFS payment methodologies. MSSP rules require CMS to develop a benchmark for savings to be achieved by each ACO, if the ACO is to receive shared savings or for ACOs that have elected to accept responsibility for losses. An ACO that meets the program’s quality performance standards will be ~~$28,689.04, which is~~eligible to receive a 1% increase. The Final Rule finalizes eight measures from Consumer Assessment of Healthcare Providers and Systems ("CAHPS") Hospice Survey data already submitted by hospices. The rule also finalizes the extensionshare of the exception for quality reporting purposes from 30 calendar days to 90 calendar days after the date that an extraordinary circumstance occurred. CMS will begin public reporting Hospice Quality Reporting Program ("HQRP") data via a Hospice Compare Site in August 2017 to help customers make informed choices. Hospices that fail to meet quality reporting requirements will receive a two percentage point reduction to their payments.

~~The following table shows the hospice Medicare payment rates for fiscal year 2018, which began on October 1, 2017 and will end September 30, 2018:~~

Description Rate per patient day
Routine Home Care days 1-60 $ 192.78
Routine Home Care days 60+ $ 151.41
Continuous Home Care $ 976.42
Full Rate = 24 hours of care
$40.68 = hourly rate
Inpatient Respite Care $ 172.78
General Inpatient Care $ 743.55

~~Community-Based Services~~

~~Community-based services are in-home care services, which are primarily performed by skilled nursing and paraprofessional personnel, and include assistance with activities of daily living~~savings to the ~~elderly, chronically ill,~~extent its assigned beneficiary medical expenditures are below its own medical expenditure benchmark provided by CMS. The Company’s HCI services segment provides specialized management services to ACOs, and ~~disabled patients. Revenue is~~in return, the Company shares in any MSSP payments received by the ACO.

Seasonality

Our home health services segment operations in Florida normally experience higher admissions during the first quarter and lower admissions during the third quarter than in the other quarters due to seasonal population fluctuations. In the second quarter of 2018, Florida operations generated ~~on an hourly basis and our current primary payors are TennCare Managed Care Organization and Medicaid. Approximately 70%~~approximately 9.7% of our net service ~~revenue in this segment was generated in Tennessee for~~revenue. Further, our third quarter falls within the ~~nine~~"hurricane season" including the peak months ~~ended September 30, 2017.~~

~~Facility-Based Services~~

~~On December 26, 2013, President Obama signed into law the Bipartisan Budget Act~~ of ~~2013 (Public Law 113-67). This law prevents a scheduled payment reduction for physicians~~August and ~~other practitioners who treat Medicare patients from taking effect on January 1, 2014. Included in the legislation are the following changes~~September. Our operations may thus be subject to ~~LTACH reimbursement:~~

~~Medicare discharges from LTACHs will continue to be paid at full LTACH PPS rates if:~~

~~the patient spent at least three days in a short-term care hospital (“STCH”) intensive care unit (“ICU”) during a STCH stay that immediately preceded the LTACH stay, or~~

~~the patient was on a ventilator for more than 96 hours in the LTACH (based on the MS-LTACH DRG assigned)~~periods of unexpected disruption, which may lower volumes and ~~had a STCH stay immediately preceding the LTACH stay.~~

~~Also, the LTACH discharge cannot have a principal diagnosis that is psychiatric or rehabilitation.~~

All other Medicare discharges from LTACHs will be paid at a new “site neutral” rate, which is the lesser of the ("IPPS") comparable per diem amount determined using the formula in the short-stay outlier regulation at 42 C.F.R. § 412.529(d)(4) plus applicable outlier payments, or 100% of the estimated cost of the services involved.

~~The above new payment policy will be effective for LTACH cost reporting periods beginning on or after October 1, 2015, and the site neutral payment rate will be phased-in over two years.~~

For cost reporting periods beginning on or after October 1, 2015, discharges paid at the site neutral payment rate or by a Medicare Advantage plan (Part C) will be excluded from the LTACH average length-of-stay (“ALOS”) calculation.

For cost reporting periods beginning in fiscal year 2016 and later, CMS will notify LTACHs of their “LTACH discharge payment percentage” (i.e., the number of discharges not paid at the site neutral payment rate divided by the total number of discharges).

For cost reporting periods beginning in fiscal year 2020 and later, LTACHs with less than 50% of their discharges paid at the full LTACH PPS rates will be switched to payment under the IPPS for all discharges in subsequent cost reporting periods. However, CMS will set up a process for LTACHs to seek reinstatement of LTACH PPS rates for applicable discharges.

MedPAC will study the impact of the above changes on quality of care, use of hospice and other post-acute care settings, different types of LTACHs and growth in Medicare spending on LTACHs. MedPAC is to submit a report to Congress with any recommendations by June 30, 2019. The report is to also include MedPAC’s assessment of whether the 25 Percent rule should continue to be applied.

On August 2, 2016, CMS released the final rule to update fiscal year 2017 LTACH reimbursement and policies under the LTACH PPS, which affects discharges occurring in cost reporting periods beginning on or after October 1, 2016. CMS projects that overall LTACH PPS spending would decrease by 7.1% compared to fiscal year 2016 payments. This estimated decrease is attributable to the statutory decrease in payment rates for site neutral LTACH PPS cases that do not meet the clinical criteria to qualify for higher LTACH rates in cost reporting years beginning on or after October 1, 2016. Cases that do qualify for higher LTACH PPS rates will see a payment rate increase of 0.7% (including a market basket update of 2.8% reduced by a multi-factor productivity adjustment of 0.3%, minus an additional adjustment of 0.75 percentage point in accordance with the PPACA, for a net market basket of 1.75%). The LTACH PPS standard federal payment rate for fiscal year 2017 is $42,476.41 (increased from $41,762.85 in fiscal year 2016). Site-neutral discharges will have a 23% reduction in payments. CMS also proposes to begin enforcement of the 25 Percent rule which will cap the number of patients treated at an LTACH who have been referred from all locations of a hospital. Grandfathered LTACH facilities are exempt from the 25 Percent rule, while rural LTACHs will have a threshold of 50% and MSA-dominant hospitals will have a threshold between 25% and 50%. The 25 Percent rule will apply to discharges occurring after October 1, 2016. CMS will have two separate outlier pools and thresholds

for LTACH-appropriate patients and for site-neutral patients. For 2017, CMS finalized an increase of its fixed-loss threshold to $21,943 from 2016’s $16,423, to limit outlier spending at no more than 8% of total LTACH spending (2016 outlier payments may reach 9.0%). CMS is applying the proposed inpatient fixed-loss threshold of $23,570 for site neutral patients. CMS also finalized four new measures for the LTACH Quality Reporting Program to meet the requirements of the Improving Medicare Post-Acute Care Transformation (IMPACT) Act. For the fiscal year 2018 LTACH Quality Reporting Program, CMS added quality measures for Medicare spending per beneficiary, discharge to community and potentially-preventable 30-day post-discharge readmissions. For the fiscal year 2020 LTACH Quality Reporting Program, CMS adopted a new drug regimen review measure.

On December 7, 2016, Congress passed the 21st Century Cures Act ("Cures"), which boosts funding for medical research, eases the development and approval of experimental treatments and reforms federal policy on mental health care. Included in the bill was relief for LTACHs under a one year moratorium on the 25 Percent Rule, which would otherwise penalize LTACHs that admit more than 25% of their patients from a particular acute care hospital. As modified by Cures, implementation of the 25 Percent Rule will be suspended during federal fiscal year 2017 (October 1, 2016 through September 30, 2017).

On August 2, 2017, CMS posted a display copy of its final rule for the annual update to Medicare payment rates and policies for the Fiscal Year 2018 inpatient hospitals prospective payment system and the LTACH PPS. CMS estimates the impact of the proposed rule will result in a 2.4% overall reduction in LTACH spending. The LTACH standard federal rate is reduced to $41,430.56 from $42,476.41. CMS is also proposing a 12 month administrative moratorium on application of the 25 Percent Rule beginning with the expiration of the statutory moratorium after September 30, 2017. The 25 Percent Rule will not be applied to LTACHs for discharges occurring on or before September 30, 2018. CMS also adopted certain adjustments to high cost outlier and short stay outlier policies. CMS finalized its proposal for a new severe wound exception to be paid at standard Federal LTACH rates instead of site neutral payments for grandfathered LTACHs. CMS changed the separateness and control restrictions for certain co-located IPPS-exempt hospitals. The Final Rule also adds three new quality measures and discontinues two quality measures. CMS also finalized its proposal to implement collection of standardized patient assessment data under the IMPACT Act on functional status, cognitive function, cancer treatments, respiratory treatments, transfusions and other special services effective for admissions on/after April 1, 2019.

None of the aforementioned estimated changes to Medicare payments for home health, hospice, and LTACHs include the deficit reduction sequester cuts to Medicare that began on April 1, 2013, which reduced Medicare payments by 2% for patients whose service dates ended on or after April 1, 2013.costs.

RESULTS OF OPERATIONS

Merger with Almost Family

On November 15, 2017, we entered into a definitive Agreement and Plan of Merger with Almost Family, providing for a "merger of equals" business combination between us and Almost Family, which we completed on April 1, 2018. The Merger created the second largest in-home healthcare provider in the country with an expanded geographic service territory of 36 states, which service territory contains over sixty percent (60%) of the U.S. population aged 65 and over and more than 770 locations, including those related to the 76 joint venture partnerships with health systems that consist of 336 hospitals.

Since the Merger was completed April 1, 2018, the first day of the Company’s second fiscal quarter, financial results of the Company for the six months ended June 30, 2018 include only one full fiscal quarter of revenues and operating income with Almost Family and its subsidiaries. The Company’s unaudited revenues and operating income for its second fiscal quarter of 2018, which included the financial results of Almost Family and its subsidiaries, was $502.0 million and $31.0 million, respectively. By comparison, for its second fiscal quarter of 2017, the Company (without combining the financial results of Almost Family and its subsidiaries) reported unaudited revenues and operating income of $257.5 million and $22.8 million, respectively, and Almost Family reported unaudited revenues and operating income of approximately $197.1 million and $9.8 million, respectively. Comparable unaudited pro forma second fiscal quarter operating results for 2017 reflected aggregate unaudited pro forma revenue and operating income of $454.7 million and $16.1 million, respectively. Unaudited pro forma information is for illustrative purposes only and may not be indicative of the results of operations that would have actually

occurred if the Merger had been completed as of the beginning of 2017. In addition, future results may vary from the results reflected in such information.

Three months ended ~~September~~June 30, ~~2017~~2018 compared to three months ended ~~September~~June 30, ~~2016~~2017

Consolidated financial statements

The following table summarizes our consolidated results of operations for the three months ended ~~September~~June 30, ~~2017~~2018 and ~~2016~~2017 (amounts in thousands, except percentages which are percentages of consolidated net service revenue, unless indicated otherwise):


	2017							2016						Increase (Decrease)			2018							2017						Increase (Decrease)
Net service revenue	$	272,872						$	230,797					$	42,075		$	502,024						$	257,535					$	244,489
Cost of service revenue	172,856			63.3	%			140,832			61.0	%		32,024			329,646			65.7	%			161,158			62.6	%		168,488
Provision for bad debts	3,194			1.2				3,275			1.4			(81		)
General and administrative expenses	75,669			27.7				66,999			29.0			8,670			141,350			28.2				73,552			28.6			67,798
(Gain) loss on disposal of assets	(177		)	(0.1	)			142			0.1			319
Interest expense	(995		)					(816		)				179			(3,202		)					(840		)				2,362
Income tax expense	7,445			41.1		(1	)	6,562			40.6		(2)	883			7,170			27.1		(1	)	7,792			41.0		(1)	(622		)
Noncontrolling interest	1,984							2,555						(571		)
Net income attributable to noncontrolling interests																	3,859							2,889						970
Net income attributable to LHC Group, Inc.’s common stockholders	$	10,906						$	9,616					$	1,290		$	16,797						$	11,304					$	5,493

(1)

Effective tax rate as a percentage of income from continuing operations attributable to LHC Group, Inc.’s common stockholders, excluding the excess tax benefits realized during the three months ended ~~September~~June 30, 2018 and 2017, of ~~$0.09~~$0.2 million and $0.3 million, respectively and the effect of capitalized transaction costs related to the Merger during the three months ended June 30, 2018 of $0.9 million. ~~For~~The change in our effective tax rate in 2018 was a ~~discussion on the excess tax benefits, see Note 2~~result of the ~~Notes to Condensed Consolidated Financial Statements,~~passage and signing of the Tax Cuts and Job Act, which ~~is incorporated herein by reference.~~reduced the Federal corporate income tax rate.


~~(2)~~	~~Effective tax rate as a percentage of income from continuing operations attributable to LHC Group, Inc.'s common stockholders.~~

Net service revenue

The following table sets forth each of our segment’s revenue growth or loss, admissions, census, episodes, patient days, and billable hours for the three months ended ~~September~~June 30, ~~2017~~2018 and the related change from the same period in ~~2016~~2017 (amounts in thousands, except admissions, census, episode data, patient days and billable ~~hours)~~hours, and revenue excludes implicit price concessions):


	Same Store(1)		De Novo(2)		Organic(3)		Organic Growth (Loss) %		Acquired(4)		Total		Total Growth (Loss) %		Same Store(1)		De Novo(2)		Organic(3)		Organic Growth (Loss) %		Acquired(4)		Total		Total Growth (Loss) %
Home health services
Revenue	$	184,467	$	327	$	184,794	10.3	%	$	14,184	$	198,978	18.8	%	$	206,678	$	1,521	$	208,199	9.0	%	$	157,714	$	365,913	88.6	%
Revenue Medicare	$	133,597	$	283	$	133,880	4.9		$	9,267	$	143,147	12.1		$	143,008	$	1,344	$	144,352	5.1		$	119,362	$	263,714	88.8
Admissions	43,122		73		43,195		6.2		4,646		47,841		17.7		50,024		296		50,320		7.9		43,585		93,905		98.0
Medicare Admissions	27,207		61		27,268		1.7		2,696		29,964		11.8		30,583		236		30,819		5.4		28,193		59,012		98.3
Average Census	39,893		50		39,943		3.7		3,507		43,450		12.8		43,207		278		43,485		2.3		33,223		76,708		77.8
Average Medicare Census	27,599		40		27,639		(1.2	)	2,052		29,691		6.1		28,590		239		28,829		(1.0	)	22,450		51,279		73.5
Home Health Episodes	50,123		75		50,198		2.0		3,805		54,003		9.7		53,277		435		53,712		2.4		42,658		96,370		81.0
Hospice services
Revenue	$	33,581	$	517	$	34,098	(3.5	)	$	7,193	$	41,291	16.9		$	39,022	$	—	$	39,022	1.6		$	12,127	$	51,149	32.8
Revenue Medicare	$	31,680	$	451	$	32,131	(2.9	)	$	5,785	$	37,916	14.6		$	34,652	$	—	$	34,652	(2.0	)	$	11,386	$	46,038	29.7
Admissions	2,451		47		2,498		(2.2	)	940		3,438		34.6		3,294		—		3,294		2.5		1,234		4,528		40.4
Medicare Admissions	2,140		40		2,180		(3.8	)	787		2,967		30.9		2,851		—		2,851		2.4		1,091		3,942		41.3
Average Census	2,651		37		2,688		(1.8	)	420		3,108		13.6		2,822		—		2,822		(6.5	)	837		3,659		20.8
Average Medicare Census	2,466		34		2,500		(1.9	)	388		2,888		13.4		2,603		—		2,603		(6.7	)	769		3,372		20.5
Patient days	244,061		3,307		247,368		(1.7	)	38,603		285,971		13.6		256,776		—		256,776		(6.5	)	76,202		332,978		20.8
Community-based services
Home and community-based services
Revenue	$	11,338	$	—	$	11,338	(3.9	)	$	808	$	12,146	3.0		$	11,840	$	—	$	11,840	9.2		$	41,924	$	53,764	395.7
Billable hours	339,569		—		339,569		(1.4	)	30,131		369,700		7.3		375,689		—		375,689		(1.4	)	1,852,142		2,227,831		484.6
Facility-based services
LTACHs
Revenue	$	15,712	$	—	$	15,712	4.5		2,561		$	18,273	21.6		$	17,727	$	—	$	17,727	25.2		$	9,977	$	27,704	95.7
Patient days	12,506		—		12,506		(7.4	)	2,093		14,599		8.1		12,382		—		12,382		(5.3	)	7,601		19,983		52.8
Other facility-based services
Revenue															$	1,075	$	—	$	1,075	(59.2	)	$	—	$	1,075	(59.2	)
HCI
Revenue															$	—	$	—	$	—	—		$	10,137	$	10,137	100.0
Consolidated
Revenue															$	276,342	$	1,521	$	277,863	8.1		$	231,879	$	509,742	95.9


(1)	Same store — location that has been in service with us for greater than 12 months.


(2)	De Novo — internally developed location that has been in service with us for 12 months or less.


(3)	Organic — combination of same store and de novo.


(4)	Acquired — purchased location that has been in service with us for 12 months or ~~less.~~less, including all legacy Almost Family locations for the period after April 1, 2018.

Total organic revenue and patient metrics increased in our home health services segment due to the successful execution of same store growth strategies. Total organic revenue and patient metrics decreased in our hospice services segment due to the lower admissions during the third quarter of 2017. Total organic revenue increased in the facility-based services segment due to patients that meet the new LTACH criteria payment model.

growth in admissions and average census in the first 24 months after acquisition, and have the highest contribution to organic growth, measured as a percentage of growth, in the second full year of operation after the acquisition.

The following table sets forth the reconciliation of total revenue disclosed above, which excludes implicit price concession, to net service revenue recognized for the three months ended June 30, 2018 and 2017 (amounts in thousands):



	Three Months Ended June 30,
	2018		% of Net Service Revenue		2017		% of Net Service Revenue
Revenue	$	509,742			$	260,210
Less: Implicit price concession	7,718		1.5	%	2,675		1.0	%
Net service revenue	$	502,024			$	257,535

Cost of service revenue

The following table summarizes cost of service revenue (amounts in thousands, except percentages, which are percentages of the segment’s respective net service revenue):


	Three Months Ended September 30,								Three Months Ended June 30,
	2017				2016				2018				2017
Home health services
Salaries, wages and benefits	$	112,117	56.3	%	$	90,393	53.9	%	$	211,631	58.7	%	$	107,044	56.3	%
Transportation	6,271		3.2		5,624		3.4		11,527		3.2		5,974		3.1
Supplies and services	4,816		2.4		4,040		2.4		7,135		2.0		4,588		2.4
Total	$	123,204	61.9	%	$	100,057	59.7	%	$	230,293	63.9	%	$	117,606	61.8	%
Hospice services
Salaries, wages and benefits	$	19,523	47.3	%	$	14,695	41.5	%	$	24,564	48.6	%	$	17,189	44.7	%
Transportation	1,588		3.8		1,329		3.8		1,872		3.7		1,534		4.1
Supplies and services	6,330		15.3		5,219		14.8		7,057		14.0		5,750		15.2
Total	$	27,441	66.5	%	$	21,243	60.1	%	$	33,493	66.3	%	$	24,473	64.0	%
Community-based services
Home and community-based services
Salaries, wages and benefits	$	8,820	72.6	%	$	8,967	76.1	%	$	39,614	75.1	%	$	7,861	73.2	%
Transportation	92		0.8		69		0.6		549		1.0		72		0.7
Supplies and services	59		0.5		64		0.5		186		0.4		53		0.5
Total	$	8,971	73.9	%	$	9,100	77.2	%	$	40,349	76.5	%	$	7,986	74.4	%
Facility-based services
Salaries, wages and benefits	$	9,644	47.1	%	$	6,987	43.2	%	$	13,706	48.4	%	$	7,698	44.5	%
Transportation	81		0.4		60		0.4		69		0.2		49		0.3
Supplies and services	3,515		17.2		3,385		21.0		5,532		19.5		3,346		20.2
Total	$	13,240	64.7	%	$	10,432	64.6	%	$	19,307	68.1	%	$	11,093	65.0	%
HCI
Salaries, wages and benefits									$	6,021	59.4	%	$	—	—	%
Transportation									163		1.6		—		—
Supplies and services									20		0.2		—		—
Total									$	6,204	61.2	%	—		—	%
Consolidated
Total									$	329,646	65.7	%	$	161,158	62.6	%

Consolidated cost of service revenue for the three months ended ~~September~~June 30, ~~2017~~2018 was ~~$172.9~~$329.6 million or ~~63.3%~~65.7% of net service revenue, compared to ~~$140.8~~$161.2 million, or ~~61.0%~~62.6% of net service revenue, for the same period in ~~2016.~~2017. Substantially all of the change in consolidated cost of service revenue was a result of the Merger and other acquisitions purchased during the latter part of 2017 and 2018. Consolidated cost of service revenue variances, excluding the acquisitions, were as follows:

•Home Health Segment -- ~~Cost~~Our same store cost of service revenue ~~increased~~ as a percentage of net service revenue increased 2.3%. This was due to in part to ~~2.0%~~1.0% Medicare reimbursement cuts recognized in ~~2017. Additionally, acquisitions accounted for $11.9 million~~2018 and annual cost of ~~the $23.1 million~~living increases. In addition, a 0.5% increase ~~with the remaining difference caused by the growth~~ in our ~~same store agencies.~~implicit price concession, which affected our net service revenue.

•Hospice Segment -- ~~Acquisitions accounted for $5.6 million of the $6.2 million increase, with the remaining difference caused by the growth in our same store agencies.~~ Cost of service increased as a percentage of net service revenue due to annual cost of living increases and the decline in ~~admissions associated with our same store agencies.~~patient days.

•Community-Based Services Segment: Cost of service revenue decreased as a percentage of net service revenue due to the utilization of contract labor in the prior year, which was used to service a higher level of care in our 2016 patient mix.

•Facility-Based Segment -- Acquisitions accounted for $2.7 million of the $2.8 million increase. Cost of service - salaries, wages, and benefits increased as a percentage of net service revenue due to lower revenue per patient day for the period caused by patient criteria changes that went into effect September 2016.

~~Provision for bad debts~~

Consolidated provision for bad debts for the three months ended September 30, 2017 was $3.2 million, or 1.2% of net service revenue, compared to $3.3 million, or 1.4% of net service revenue, for the same period in 2016. The Company continues to have more timely cash collections and an increase in amounts collected. The continued maturity of our back office and field operations, use of our point-of-care platform, and use of other technology advancements in reporting and analytics are drivers of collection improvements.

General and administrative expenses

The following table summarizes general and administrative expenses (amounts in thousands, except percentages, which are percentages of the segment’s respective net service revenue):


	Three Months Ended September 30,								Three Months Ended June 30,
	2017				2016				2018				2017
Home health services
General and administrative	$	53,753	27.0	%	$	48,282	28.8	%	$	96,791	26.9	%	$	53,137	27.6	%
Depreciation and amortization	2,227		1.1		2,011		1.2		2,371		0.7		2,131		1.1
Total	$	55,980	28.1	%	$	50,293	30.0	%	$	99,162	27.5	%	$	55,268	28.7	%
Hospice services
General and administrative	$	10,697	25.9	%	$	8,941	25.3	%	$	13,979	27.7	%	$	10,199	26.9	%
Depreciation and amortization	566		1.4		550		1.6		634		1.3		544		1.4
Total	$	11,263	27.3	%	$	9,491	26.9	%	$	14,613	28.9	%	$	10,743	28.3	%
Community-based services
Home and community-based services
General and administrative	$	2,275	18.7	%	$	2,158	18.3	%	$	11,582	22.0	%	$	2,149	20.0	%
Depreciation and amortization	112		0.9		105		0.9		195		0.4		112		1.0
Total	$	2,387	19.6	%	$	2,263	19.2	%	$	11,777	22.4	%	$	2,261	21.0	%
Facility-based services
General and administrative	$	5,613	27.4	%	$	4,506	27.9	%	$	10,351	36.6	%	$	4,908	29.7	%
Depreciation and amortization	427		2.1		446		2.8		737		2.6		372		2.3
Total	$	6,040	29.5	%	$	4,952	30.7	%	$	11,088	39.2	%	$	5,280	32.0	%
HCI
General and administrative									$	4,331	42.7	%	$	—	—	%
Depreciation and amortization									379		3.7		—		—
Total									$	4,710	46.4	%	$	—	—	%
Consolidated
Total									$	141,350	28.2	%	$	73,552	28.6	%

Consolidated general and administrative expenses for the three months ended ~~September~~June 30, ~~2017~~2018 were ~~$75.7~~$141.4 million, or ~~27.7%~~28.2% of net service revenue, compared to ~~$67.0~~$73.6 million, or ~~29.0%~~28.6% of net service revenue, for the same period in ~~2016. Although~~2017. Substantially all of the change in consolidated general and administrative expenses ~~increased~~was a result of the Merger and other acquisitions purchased during the latter part of 2017 and 2018. The increase in ~~total over the same period in 2016, they decreased as a percentage of net service revenue by 1.3%. We continue to leverage efficiencies found in our back office that allow us to maintain~~ general and administrative ~~costs without increasing costs~~expenses in ~~proportion~~the facility-based services segment was due in part to the ~~growth~~closure of ~~our company.~~two LTACH locations and the relocation of two other LTACH locations.

~~Nine~~Six months ended ~~September~~June 30, ~~2017~~2018 compared to ~~nine~~six months ended ~~September~~June 30, ~~2016~~2017

Consolidated financial statements

The following table summarizes our consolidated results of operations for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and ~~2016~~2017 (amounts in thousands, except percentages which are percentages of consolidated net service revenue, unless indicated otherwise):


	2017							2016						Increase (Decrease)			2018							2017						Increase (Decrease)
Net service revenue	$	779,700						$	679,380					$	100,320		$	793,078						$	501,784					$	291,294
Cost of service revenue	488,384			62.6	%			413,561			60.9	%		74,823			518,264			65.3	%			315,528			62.9	%		202,736
Provision for bad debts	8,238			1.1				11,658			1.7			(3,420		)
General and administrative expenses	221,077			28.4				201,296			29.6			19,781			233,381			29.4				145,563			29.0			87,818
(Gain) loss on disposal of assets	(23		)	—				1,389			0.2			1,412
Interest expense	(2,615		)					(2,167		)				448			(4,652		)					(1,620		)				3,032
Income tax expense	20,410			41.0		(1	)	15,500			40.5		(2)	4,910			8,147			27.5		(1	)	12,965			41.0		(1)	(4,818		)
Noncontrolling interest	7,321							7,043						278
Net income attributable to noncontrolling interests																	6,842							5,337						1,505
Net income attributable to LHC Group, Inc.’s common stockholders	$	31,678						$	26,766					$	4,912		$	21,792						$	20,771					$	1,021

(1)

Effective tax rate as a percentage of income from continuing operations attributable to LHC Group, Inc.’s common stockholders, excluding the excess tax benefits realized during the ~~nine~~six months ended ~~September~~June 30, 2018 and 2017 of ~~$1.0 million. For~~$0.9 million and $1.1 million, respectively. The change in our effective tax rate in 2018 was a ~~discussion on the excess tax benefits, see Note 2~~result of the ~~Notes to Condensed Consolidated Financial Statements, which is incorporated herein by reference.~~


~~(2)~~	~~Effective tax rate as a percentage of income from continuing operations attributable to LHC Group, Inc.’s common stockholders, excluding the changes in measurement realized in 2016~~passage and signing of the ~~unrecognized~~Tax Cuts and Job Act, which reduced the Federal corporate income tax ~~position of $1.6 million and related interest expense of $0.4 million.~~rate.

Net service revenue

The following table sets forth each of our segment’s revenue growth or loss, admissions, census, episodes, patient days, and billable hours for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 and the related change from the same period in ~~2016~~2017 (amounts in thousands, except admissions, census, episode data, patient days and billable ~~hours)~~hours, and revenue excludes implicit price concessions):


	Same Store(1)		De Novo(2)		Organic(3)		Organic Growth (Loss) %		Acquired(4)		Total		Total Growth (Loss) %		Same Store(1)		De Novo(2)		Organic(3)		Organic Growth (Loss) %		Acquired(4)		Total		Total Growth (Loss) %
Home health services
Revenue	$	541,918	$	990	$	542,908	10.3	%	$	32,272	$	575,180	16.9	%	$	400,360	$	3,169	$	403,529	9.0	%	$	169,913	$	573,442	52.4	%
Revenue Medicare	$	394,756	$	826	$	395,582	5.6		$	19,973	$	415,555	10.9		$	278,322	$	2,875	$	281,197	4.9		$	128,767	$	409,964	50.5
Admissions	130,012		219		130,231		9.7		12,610		142,841		20.3		99,231		643		99,874		7.2		47,154		147,028		55.2
Medicare Admissions	82,898		176		83,074		5.5		6,715		89,789		14.0		60,885		525		61,410		4.8		30,630		92,040		54.5
Average Census	39,819		47		39,866		4.0		2,996		42,862		11.9		42,674		331		43,005		2.9		33,511		76,516		80.5
Average Medicare Census	27,829		38		27,867		(0.7	)	1,660		29,527		5.2		28,388		284		28,672		(0.8	)	22,618		51,290		75.0
Home Health Episodes	149,670		234		149,904		1.2		9,241		159,145		7.4		103,730		789		104,519		1.0		46,171		150,690		43.5
Hospice services
Revenue	$	99,410	$	1,001	$	100,411	0.4		$	15,838	$	116,249	16.2		$	75,045	$	—	$	75,045	0.6		$	19,472	$	94,517	26.1
Revenue Medicare	$	93,073	$	892	$	93,965	0.9		$	13,609	$	107,574	15.6		$	68,385	$	—	$	68,385	(1.4	)	$	17,281	$	85,666	23.0
Admissions	7,729		1		7,730		2.5		1,987		9,717		28.9		6,469		—		6,469		3.8		2,113		8,582		36.7
Medicare Admissions	6,663		1		6,664		—		1,696		8,360		25.4		5,643		—		5,643		5.3		1,848		7,491		38.9
Average Census	2,533		24		2,557		(1.4	)	431		2,988		15.2		2,497		—		2,497		(14.3	)	902		3,399		16.2
Average Medicare Census	2,341		22		2,363		(1.9	)	406		2,769		14.9		2,316		—		2,316		(14.1	)	827		3,143		16.1
Patient days	716,644		6,504		723,148		1.8		92,607		815,755		14.8		500,478		—		500,478		(5.1	)	114,720		615,198		16.2
Community-based services
Home and community-based services
Revenue	$	32,125	$	—	$	32,125	(2.1	)	$	1,682	$	33,807	3.0		$	23,597	$	—	$	23,597	8.9		$	44,474	$	68,071	214.3
Billable hours	1,014,930		—		1,014,930		3.6		41,292		1,056,222		7.8		766,687		—		766,687		1.8		1,939,927		2,706,614		259.5
Facility-based services
LTACHs
Revenue	$	44,330	$	—	$	44,330	(13.2	)	2,561		$	46,891	(8.2	)	$	35,666	$	—	$	35,666	22.6		$	20,190	$	55,856	92.0
Patient days	39,313		—		39,313		(8.5	)	2,093		41,406		(3.6	)	25,652		—		25,652		(4.3	)	15,385		41,037		53.1
Other facility-based services
Revenue															$	3,699	$	—	$	3,699	(24.8	)	$	—	$	3,699	(24.8	)
HCI
Revenue															$	—	$	—	$	—	—		$	10,137	$	10,137	100.0
Consolidated
Revenue															$	538,367	$	3,169	$	541,536	8.2		$	264,186	$	805,722	59.0


(1)	Same store — location that has been in service with us for greater than 12 months.


(2)	De Novo — internally developed location that has been in service with us for 12 months or less.


(3)	Organic — combination of same store and de novo.


(4)	Acquired — purchased location that has been in service with us for 12 months or ~~less.~~less, including all legacy Almost Family locations for the period after April 1, 2018.

Total organic revenue and patient metrics increased in our home health services segment and hospice services segment due to the successful execution of same store growth strategies. Total organic revenue and patient days decreased in the facility-based services segment due to the negative impact from the reduction of LTACH beds and lower revenue per patient day caused by patient criteria changes that went into effect in June 2016 and September 2016.

Organic growth is primarily generated by population growth in areas covered by mature agencies, agencies five years old or older, and by increased market share in acquired and developing agencies. Historically, acquired agencies have the highest growth in admissions and average census in the first 24 months after acquisition, and have the highest contribution to organic growth, measured as a percentage of growth, in the second full year of operation after the acquisition.

The following table sets forth the reconciliation of total revenue disclosed above, which excludes implicit price concession, to net service revenue recognized for the six months ended June 30, 2018 and 2017 (amounts in thousands):



	Six Months Ended June 30,
	2018		% of Net Service Revenue		2017		% of Net Service Revenue
Revenue	$	805,722			$	506,828
Less: Implicit price concession	12,644		1.6	%	5,044		1.0	%
Net service revenue	$	793,078			$	501,784

Cost of service revenue

The following table summarizes cost of service revenue (amounts in thousands, except percentages, which are percentages of the segment’s respective net service revenue):


	Nine Months Ended September 30,								Six Months Ended June 30,
	2017				2016				2018				2017
Home health services
Salaries, wages and benefits	$	320,933	55.8	%	$	266,170	54.1	%	$	330,297	58.5	%	$	208,816	56.0	%
Transportation	18,064		3.1		16,648		3.4		18,033		3.2		11,793		3.2
Supplies and services	13,899		2.4		11,541		2.3		12,123		2.1		9,083		2.4
Total	$	352,896	61.3	%	$	294,359	59.8	%	$	360,453	63.8	%	$	229,692	61.6	%
Hospice services
Salaries, wages and benefits	$	52,800	45.4	%	$	43,319	43.3	%	$	45,053	48.4	%	$	33,277	45.1	%
Transportation	4,555		3.9		4,005		4.0		3,496		3.8		2,967		4.0
Supplies and services	17,832		15.3		14,512		14.5		12,963		13.9		11,502		15.6
Total	$	75,187	64.6	%	$	61,836	61.8	%	$	61,512	66.1	%	$	47,746	64.7	%
Community-based services
Home and community-based services
Salaries, wages and benefits	$	24,514	72.5	%	$	24,256	73.9	%	$	50,261	75.2	%	$	15,694	73.7	%
Transportation	231		0.7		197		0.6		639		1.0		139		0.7
Supplies and services	160		0.5		203		0.6		239		0.4		101		0.5
Total	$	24,905	73.7	%	$	24,656	75.1	%	$	51,139	76.6	%	$	15,934	74.9	%
Facility-based services
Salaries, wages and benefits	$	24,959	45.8	%	$	21,626	39.7	%	$	27,362	46.8	%	$	15,316	45.5	%
Transportation	199		0.4		190		0.3		148		0.3		117		0.3
Supplies and services	10,238		18.8		10,894		20.0		11,446		19.6		6,723		20.0
Total	$	35,396	65.0	%	$	32,710	60.0	%	$	38,956	66.7	%	$	22,156	65.9	%
HCI
Salaries, wages and benefits									$	6,021	59.4	%	$	—	—	%
Transportation									163		1.6		—		—
Supplies and services									20		0.2		—		—
Total									$	6,204	61.2	%	$	—	—	%
Consolidated
Total									$	518,264	65.3		$	315,528	62.9

Consolidated cost of service revenue for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 was ~~$488.4~~$518.3 million or ~~62.6%~~ 65.3%of net service revenue, compared to ~~$413.6~~$315.5 million, or ~~60.9%~~62.9% of net service revenue, for the same period in ~~2016.~~2017. Substantially all of the change in consolidated cost of service revenue was a result of the Merger and other acquisitions purchased during the latter part of 2017 and 2018. Consolidated cost of service revenue variances, excluding the acquisitions, were as follows:

•Home Health Segment -- ~~Cost~~Our same store cost of service revenue ~~increased~~ as a percentage of net service revenue increased 2.8%, which was due in part to ~~2.0%~~1.0% Medicare reimbursement cuts recognized in ~~2017. Additionally, acquisitions accounted for $32.5 million~~2018 and annual cost of ~~the $58.5 million~~living increases. In addition, a 0.6% increase ~~with the remaining difference caused by growth~~ in our ~~same store agencies.~~implicit price concession, which affected our net service revenue.

•Hospice Segment -- ~~Acquisitions accounted for $6.6 million of the $13.4 million increase in cost of service revenue, with the remaining difference caused by growth in our same store agencies.~~ Cost of service increased as a percentage of net service revenue due to annual cost of living increases and the decline in ~~same store admissions during the third quarter of 2017.~~

•Facility-Based Services Segment -- Acquisitions accounted for $3.0 million of the $2.7 million increase in cost of service revenue, which was offset by decrease in cost of service for one LTACH location that had a reduction of beds during 2016. Cost of service revenue increased as a percentage of net service revenue due to lower revenue per patient day for the period caused by patient criteria changes that went into effect in June 2016 and September 2016.

~~Provision for bad debts~~

Consolidated provision for bad debts for the nine months ended September 30, 2017 was $8.2 million, or 1.1% of net service revenue, compared to $11.7 million, or 1.7% of net service revenue, for the same period in 2016. The decrease in provision for bad debts was primarily due to continued process improvements implemented in our revenue cycle department. These improvements also contributed to the significant decrease in patient accounts receivable that are over 180 days. The Company continues to have more timely cash collections and an increase in amounts collected. The continued maturity of our

~~back office and field operations, use of our point-of-care platform, and use of other technology advancements in reporting and analytics are drivers of collection improvements.~~

General and administrative expenses

The following table summarizes general and administrative expenses (amounts in thousands, except percentages, which are percentages of the segment’s respective net service revenue):


	Nine Months Ended September 30,								Six Months Ended June 30,
	2017				2016				2018				2017
Home health services
General and administrative	$	158,713	27.6	%	$	145,166	29.5	%	$	160,902	28.5	%	$	104,959	28.1	%
Depreciation and amortization	6,440		1.1		5,782		1.2		4,550		0.8		4,231		1.1
Total	$	165,153	28.7	%	$	150,948	30.7	%	$	165,452	29.3	%	$	109,190	29.2	%
Hospice services
General and administrative	$	30,675	26.4	%	$	26,175	26.2	%	$	26,773	28.7	%	$	19,978	27.1	%
Depreciation and amortization	1,729		1.5		1,612		1.6		1,137		1.2		1,171		1.6
Total	$	32,404	27.9	%	$	27,787	27.8	%	$	27,910	29.9	%	$	21,149	28.7	%
Community-based services
Home and community-based services
General and administrative	$	6,621	19.6	%	$	6,260	19.1	%	$	14,766	22.1	%	$	4,348	20.4	%
Depreciation and amortization	336		1.0		297		0.9		309		0.5		224		1.1
Total	$	6,957	20.6	%	$	6,557	20.0	%	$	15,075	22.6	%	$	4,572	21.5	%
Facility-based services
General and administrative	$	15,388	28.3	%	$	14,672	27.0	%	$	19,188	32.8	%	$	9,776	29.1	%
Depreciation and amortization	1,175		2.2		1,332		2.4		1,046		1.8		876		2.6
Total	$	16,563	30.5	%	$	16,004	29.4	%	$	20,234	34.6	%	$	10,652	31.7	%
HCI
General and administrative									$	4,331	42.7	%	$	—	—	%
Depreciation and amortization									379		3.7		—		—
Total									$	4,710	46.4	%	$	—	—	%
Consolidated
Total									$	233,381	29.4	%	$	145,563	29.0	%

Consolidated general and administrative expenses for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 were ~~$221.1~~$233.4 million or ~~28.4%~~29.4% of net service revenue, compared to ~~$201.3~~$145.6 million, or ~~29.6%~~29.0% of net service revenue, for the same period in ~~2016. Although~~2017. Substantially all of the change in consolidated general and administrative expenses ~~increased~~was a result of the Merger and other acquisitions purchased during the latter part of 2017 and 2018. The increase in ~~total over the same period in 2016, they decreased as a percentage of net service revenue by 1.2%. We continue to leverage efficiencies found in our back office that allows us to maintain~~ general and administrative ~~costs without increasing costs~~expenses in ~~proportion~~the facility-based services segment was due in part to the ~~growth~~closure of ~~our company.~~

~~Loss on disposal~~two LTACH locations and the relocation of ~~assets~~

The loss on disposal of assets increased during the nine months ended September 30, 2016 primarily due to the sale of an aircraft. The aircraft incurred damage and was subsequently sold at a price below the aircraft's net book value. The sale generated a loss of $0.9 million, which was realized during the nine months ended September 30, 2016.

two other LTACH locations.

LIQUIDITY AND CAPITAL RESOURCES

Liquidity

Our principal source of liquidity for operating activities is the collection of patient accounts receivable, most of which are collected from governmental and third party commercial payors. We also have the ability to obtain additional liquidity, if necessary, through our credit facility, which provides for aggregate borrowings, including outstanding letters of ~~credit, up to $225 million. As of September 30, 2017, we had $95.0 million available for borrowing under our credit facility.~~credit.

The following table summarizes changes in cash (amounts in thousands):


	Nine Months Ended September 30,						Six Months Ended June 30,
	2017			2016			2018			2017
Net cash provided by (used in):
Operating activities	$	61,695		$	57,843		$	29,698		$	42,776
Investing activities	(69,191		)	(34,635		)	(674		)	(28,568		)
Financing activities	21,154			(12,829		)	(16,503		)	(10,504		)

Cash provided by operating activities and cash used in investing activities varied due to net changes in operating assets and liabilities primarily related to acquisitions acquired in 2017. Cash used in financing activities changed primarily due to the ~~increased collections in patient accounts receivable, accretion~~line of ~~acquisitions purchased in 2016, and accretion of our same store agencies.~~

~~Accounts Receivable and Allowance for Uncollectible Accounts~~

For home health services, hospice services, and community-based services, we calculate the allowance for uncollectible accounts as a percentage of total patient receivables. The percentage changes depending on the payor and increases as the patient receivables age. For facility-based services, we calculate the allowance for uncollectible accounts based on a claim by claim review.

As of September 30, 2017, our allowance for uncollectible accounts, as a percentage of patient accounts receivable, was approximately 15.2%, or $26.1 million, compared to 18.9% or $29.0 million at December 31, 2016. Days sales outstanding was 49 days for September 30, 2017 and December 31, 2016.

~~The following table sets forth as of September 30, 2017, the aging of accounts receivable (amounts in thousands):~~

Payor 0-90 91-180 181-365 Over 365 Total
Medicare $ 78,600
$ 14,145
$ 2,725
$ 6,196
$ 101,666
Medicaid 5,507
2,588
614
1,393
10,102
Other 38,804
8,860
6,557
5,608
59,829
Total $ 122,911
$ 25,593
$ 9,896
$ 13,197
$ 171,597

~~The following table sets forth as of December 31, 2016, the aging of accounts receivable (amounts in thousands):~~

Payor 0-90 91-180 181-365 Over 365 Total
Medicare $ 71,386
$ 9,590
$ 5,547
$ 5,720
$ 92,243
Medicaid 4,600
1,470
1,380
268
7,718
Other 33,084
5,943
7,179
7,672
53,878
Total $ 109,070
$ 17,003
$ 14,106
$ 13,660
$ 153,839
credit activity.

Indebtedness

AsDuring the period from January 1, 2018 through April 1, 2018, we maintained our revolving line of ~~September 30, 2017, we had $95.0 million available for borrowing under our~~credit through a credit facility with $119.0 million drawn under our credit facility and $11.0 million of letters of credit outstanding. At December 31, 2016, we had $87.0 million drawn and $11.0 million of letters of credit outstanding under our credit facility.

~~For a discussion on our Credit Agreement~~agreement with Capital One, National Association ~~see Note 5~~which had a scheduled maturity of June 18, 2019 (the "Prior Credit Facility"). The interest rate for borrowing under the Prior Credit Facility was a variable rate which is a function of the ~~Notes to Condensed Consolidated Financial Statements,~~prime rate (base rate) or London Interbank Offered Rate ("LIBOR") as elected by us, plus the applicable margin based on the Leverage Ratio.

On March 30, 2018, we entered into a Credit Agreement with JPMorgan Chase Bank, N.A., which ~~is incorporated herein by reference.~~

Awas effective on April 2, 2018 (the "New Credit Agreement"). The New Credit Agreement provides a senior, secured revolving line of credit commitment with a maximum principal borrowing limit of $500.0 million, which includes an additional $200.0 million accordion expansion feature, and a letter of credit sub-limit equal to $50.0 million. The expiration date of the New Credit Agreement is March 30, 2023. Our obligations under the New Credit Agreement are secured by substantially all of the assets of the Company and its wholly-owned subsidiaries, which assets include the Company’s equity ownership of its wholly-owned subsidiaries and its equity ownership in joint venture entities. Our wholly-owned subsidiaries also guarantee the obligations of the Company under the New Credit Agreement. Debt issuance costs of $1.9 million were capitalized with the New Credit Agreement and will be amortized through March 30, 2023, the termination date for the New Credit Agreement.

Revolving loans under the New Credit Agreement bear interest at, as selected by us, either a (a) Base Rate, which is defined as a fluctuating rate per annum equal to the highest of (1) the Federal Funds Rate in effect on such day plus 0.5%, (2) the Prime Rate in effect on such day, and (3) the Eurodollar Rate for a one month interest period on such day plus 1.5%, plus a margin ranging from 0.50% to 1.25% per annum or (b) Eurodollar rate plus a margin ranging from 1.50% to 2.25% per annum. Swing line loans bear interest at the Base Rate. We are limited to 15 Eurodollar borrowings outstanding at the same time. We are required to pay a commitment fee for the unused commitments at rates ranging from 0.20% to 0.35% per annum depending upon our consolidated Leverage Ratio, as defined in the New Credit Agreement. The effective interest rates on our borrowings under the New Credit Agreement were 3.85% as of June 30, 2018.

On April 2, 2018, in connection with the consummation of the Merger, we borrowed approximately $247.4 million under the New Credit Agreement to (i) repay the approximately $107.3 million of outstanding borrowings under Almost Family’s prior credit facility with JPMorgan Chase Bank, N.A., which was terminated in connection with the Merger, (ii) repay the approximately $125.1 million of outstanding borrowings under the Prior Credit Facility, which was also terminated in connection with the Merger, and (iii) pay certain debt issuance and repayment costs and Merger related fees and expenses.

At December 31, 2017, we had $144.0 million drawn and letters of credit outstanding in the amount of $9.6 million under our Prior Credit Facility. As of June 30, 2018, we had $242.0 million drawn and letters of credit outstanding in the amount of $25.1 million under the New Credit Agreement, and had approximately $232.9 million of remaining borrowing capacity available under the New Credit Agreement.

Under the New Credit Agreement with JPMorgan Chase Bank, N.A., a letter of credit fee shall be equal to the applicable Eurodollar rate ~~multiplied-by~~on the ~~face~~average daily amount of the letter of credit ~~is charged upon the issuance and on each anniversary date while the letter of credit is outstanding.~~exposure. The agent’s standard up-front fee and other

customary administrative charges will also be due upon issuance of the letter of credit along with a renewal fee on each anniversary date of such issuance while the letter of credit is outstanding. Borrowings accrue interest under the Credit Agreement at either the Base Rate or the Eurodollar rate, and are subject to the applicable margins set forth below:

Leverage Ratio
Eurodollar
Margin

Base
Rate
Margin

Commitment
Fee Rate
≤1.00:1.00 1.75 % 0.75 % 0.225 %
>1.00:1.00 ≤ 1.50:1.00 2.00 % 1.00 % 0.250 %
>1.50:1.00 ≤ 2.00:1.00 2.25 % 1.25 % 0.300 %
>2.00:1.00 2.50 % 1.50 % 0.375 %



Leverage Ratio	Eurodollar Margin		Base Rate Margin		Commitment Fee Rate
≤1.00:1.00	1.50	%	0.50	%	0.200	%
>1.00:1.00 ≤ 2.00:1.00	1.75	%	0.75	%	0.250	%
>2.00:1.00 ≤ 3.00:1.00	2.00	%	1.00	%	0.300	%
>3.00:1.00	2.25	%	1.25	%	0.350	%

Our New Credit Agreement contains customary affirmative, negative and financial ~~covenants. For example, without prior approval~~covenants, which are subject to customary carve-outs, thresholds, and materiality qualifiers. The Credit Facility allows us to make certain restricted payments within certain parameters provided we maintain compliance with those financial ratios and covenants after giving effect to such restricted payments or, in the case of ~~our bank group, we~~repurchasing shares of its stock, so long as such repurchases are ~~materially restricted in incurring additional debt, disposing of assets, making investments, allowing fundamental changes to our business or organization, and making~~within certain payments in respect of stock or other ownership interests, such as dividends and stock repurchases, up to $50 million. Under our Credit Agreement, we are also required to meet certain financial covenants with respect to minimum fixed charge coverage and leverage ratios.specified baskets.

Our New Credit Agreement also contains customary events of ~~default.~~default, which are subject to customary carve-outs, thresholds, and materiality qualifiers. These include bankruptcy and other insolvency events, cross-defaults to other debt agreements, a change in control involving us or any subsidiary guarantor, and the failure to comply with certain covenants.

At ~~September~~June 30, ~~2017,~~2018, we were in compliance with all ~~covenants contained in the Credit Agreement governing our credit facility.~~debt covenants.

Contingencies

For a discussion of contingencies, see Note 78 of the Notes to Condensed Consolidated Financial Statements, which is incorporated herein by reference.

Off-Balance Sheet Arrangements

We do not currently have any off-balance sheet arrangements with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts. As such, we are not materially exposed to any financing, liquidity, market, or credit risk that could arise if we had engaged in these relationships.

Critical Accounting Policies

For a discussion of critical accounting policies, see Note 2 of the Notes to Condensed Consolidated Financial Statements, which is incorporated herein by reference.

~~Accounts Receivable and Allowances for Uncollectible Accounts~~

We report accounts receivable net of estimated allowances for uncollectible accounts and adjustments. Accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors, and patients. To provide for accounts receivable that could become uncollectible in the future, we establish an allowance for uncollectible accounts to reduce the carrying amount of such receivables to their estimated net realizable value.

The collection of outstanding receivables is our primary source of cash collections and is critical to our operating performance. Because Medicare is our primary payor, the credit risk associated with receivables from other payors is limited. We believe the credit risk associated with our Medicare accounts, which historically exceeds 50% of our patient accounts receivable as of September 30, 2017 and December 31, 2016, respectively, is limited due to (i) the historical collections from Medicare and (ii) the fact that Medicare is a U.S. government payor. We do not believe that there are any other significant concentrations of receivables from any particular payor that would subject us to any significant credit risk in the collection of accounts receivable.

The amount of the provision for bad debts is based upon our assessment of historical and expected net collections, business and economic conditions and trends in government reimbursement. Quarterly, we perform a detailed review of historical writeoffs and recoveries as well as recent collection trends. Uncollectible accounts are written off when we have exhausted collection efforts and concluded the account will not be collected.

Although our estimated reserves for uncollectible accounts are based on historical experience and the most current collection trends, this process requires significant judgment and interpretation of the observed trends and the actual collections could differ from our estimates.

Insurance

We retain ~~significant exposure~~coverage for our employee health insurance, workers compensation, employment practices, and professional liability insurance programs. Our insurance programs require us to estimate potential payments on filed claims and/or claims incurred but not reported. Our estimates are based on information provided by the third-party plan administrators, historical claim experience, expected costs of claims incurred but not paid and expected costs associated with settling claims. Each month, we review the insurance-related recoveries and liabilities to determine if any adjustments are required.

Our employee health insurance program is self-funded, with stop-loss coverage on claims that exceed $0.2 million for any individually covered employee or employee family member. We are responsible for workers’ compensation claims up to $0.5 million per individual incident.

Malpractice, employment practices, and general liability claims for incidents which may give rise to litigation have been asserted against us by various claimants. The claims are in various stages of processing and some may ultimately be brought to trial. We are aware of incidents that have occurred through ~~September~~June 30, ~~2017~~2018 that may result in the assertion of additional claims. We currently carry professional, general liability and employment practices insurance coverage (on a claims made basis) for this exposure.

We also carry D&O coverage (also on a claims made basis) for potential claims against our directors and officers, including securities actions, with a deductible of $1.0 million per security claim and $0.5 million on other claims. Pursuant to the terms of the Agreement and Plan of Merger with Almost Family, for six years following the Merger, the Company will maintain in effect Almost Family’s directors’ and officers’ liability insurance policy covering each person covered by such policy for acts or omissions occurring prior to and through the effective time of the Merger. In lieu of maintaining Almost Family’s policies, the Company may (i) substitute policies of an insurance company with the same or better rating as Almost Family’s insurance carrier, the material terms of which, including coverage and amount, are no less favorable in any material respect than Almost Family’s policies as of the effective date of the Merger, or (ii) obtain extended reporting period coverage under Almost Family’s insurance programs for a period of six years after the effective time of the Merger.

We estimate our liabilities related to these programs using the most current information available. As claims develop, we may need to change the recorded liabilities and change our estimates. These changes and adjustments could be material to our financial statements, results of operations and financial condition.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Our exposure to market risk relates to changes in interest rates for borrowings under our credit facility. Our letter of credit fees and interest accrued on our debt borrowings are subject to the applicable Eurodollar or Base Rate. A hypothetical basis point increase in interest rates on the average daily amounts outstanding under the credit facility would have increased interest expense by ~~$0.7~~$1.0 million for the ~~nine~~six months ended ~~September~~June 30, ~~2017.~~2018.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) that are designed to ensure that information that we are required to disclose in our reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report.

Based on the evaluation of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) were effective as of ~~September~~June 30, ~~2017.~~2018.

Changes in Internal Controls Over Financial Reporting

~~There~~Except in connection with the orderly integration of the operations and financial reporting of Almost Family following the Merger, there have not been any changes in our internal control over financial reporting, as such term is defined in Rule 13a-15(f) of the Exchange Act, during the quarterly period ended ~~September~~June 30, ~~2017~~2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. On April 1, 2018, the Company completed the Merger. The Company is in the process of integrating Almost Family into the Company's existing internal control environment. As permitted by the SEC, the Company expects to exclude Almost Family from the assessment of internal control over financial reporting as of December 31, 2018.

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

For a discussion of legal proceedings, see Note 78 of the Notes to Condensed Consolidated Financial Statements, which is incorporated herein by reference.

ITEM 1A. RISK FACTORS.

~~There have been no material changes~~Important risk factors that could affect the Company’s operations and financial performance, or that could cause results or events to differ from ~~the information included~~current expectations, are described in Part I, Item 1A., “Risk Factors” of the Company’s ~~2016~~2017 Annual Report on Form 10-K. Those risk factors are supplemented by those discussed under “Management’s Discussion And Analysis Of Financial Condition And Results Of Operations” in Part I, Item 2 of this report. Furthermore, as a result of the Merger with Almost Family and recent regulatory developments, the risk factors discussed below have been identified as additional risk factors to those previously reported in the Company’s 2017 Annual Report on Form 10-K (dollars in thousands).

Portions of our Healthcare Innovations (HCI) segment compete in relatively new and developing markets, face larger more well-capitalized competitors, and rely on small numbers of relatively large customers.

The Company’s HCI segment is used to report on the Company’s developmental activities other than home health, hospice, home and community-based services, and facility-based services. The HCI segment includes (a) Imperium Health Management, LLC, an ACO enablement company, (b) Long Term Solutions, Inc., an in-home assessment company serving the long-term care insurance industry, and certain assets operated by Advanced Care House Calls, which provides primary medical care for home-bound or home-limited patients with chronic and acute illnesses who have difficulty traveling to a doctor’s office (c) Ingenios Health Co., a Nurse-Practitioner-oriented and mobile technology-enabled health risk assessment company primarily serving managed care organizations, and (d) an investment in Care Journey (formerly NavHealth, Inc.), a population-health analytics company. Portions of our HCI segment compete in new and developing markets with new competitors or solutions developed and introduced to the market regularly. Such new products may capture market share more quickly or may have access to more capital than the capital we have allocated for such projects. Our efforts to bring new solutions to the market may prove unsuccessful, may prove to be unprofitable, or may prove to be costlier to bring to market than anticipated. Our investments in these activities are highly speculative in nature and subject to loss. Specifically, our assessment subsidiary competes with larger, better capitalized competitors, while also being particularly reliant on a small number of large customers, the loss of which could significantly and adversely impact its results.

We have invested in development stage companies which may require further funding to support their respective business plans, which may ultimately prove unsuccessful.

In conjunction with the Merger, we obtained controlling interests in (a) Imperium Health Management, LLC, an ACO enablement and management company, (b) Ingenios Health Co. a provider of in-home technology enabled in-home clinical assessments, (c) Long Term Solutions, Inc., a provider of in-home nursing assessments for the long-term care insurance industry; and certain assets operated by Advanced Care House Calls, which provides primary medical care for home-bound or home-limited patients with chronic and acute illnesses who have difficulty traveling to a doctor’s office, as well as (d) a noncontrolling interest in Care Journey (formerly NavHealth, Inc.), a development stage analytics and software company. These investments are highly speculative, at risk and we may choose to make further investments, all of which may ultimately provide no return and could lead to a total loss of our investment. These investments collectively comprise our HCI segment.

Our HCI segment provides strategic health management services to Accountable Care Organizations (“ACOs”) that have been approved to participate in the Medicare Shared Savings Program (“MSSP”). ACOs are entities that contract with CMS to serve the Medicare fee-for-service population with the goal of better care for individuals, improved health for populations and lower costs. ACOs share savings with CMS to the extent that the actual costs of serving assigned beneficiaries are below certain trended benchmarks of such beneficiaries and certain quality performance measures are achieved. In addition to our ownership interests in ACOs, we also have management service agreements with ACOs that provide for sharing of MSSPs received by the ACOs, if any.

Notwithstanding our efforts, our ACOs may be unable to meet the required savings rates or may not satisfy the quality measures and efforts to drive other revenue may not cover operating costs of these investments. In addition, as the MSSP is a

new program, it presents challenges and risks associated with the timeliness and accuracy of data and interpretation of complex rules, which may have a material adverse effect on our ability to recoup any of our investments. Further, there can be no assurance that we will maintain positive relations with our ACO partners or significant customers, which could result in a loss of our investment.

In addition, CMS, the OIG, the Internal Revenue Service, the Federal Trade Commission, US Department of Justice, and various states have adopted or are considering adopting new legislation, rules, regulations and guidance relating to formation and operation of ACOs. Such laws may, among other things, require ACOs to become subject to financial regulation such as maintaining deposits of assets with the states in which they operate, the filing of periodic reports with the insurance department and/or department of health, or holding certain licenses or certifications in the jurisdictions in which the ACOs operate. Failure to comply with legal or regulatory restrictions may result in CMS terminating the ACO's agreement with CMS and/or subjecting the ACO to loss of the right to engage in some or all business in a state, payments fines or penalties, or may implicate federal and state fraud and abuse laws relating to anti-trust, physician fee-sharing arrangements, anti-kickback prohibitions, prohibited referrals, any of which may adversely affect our operations and/or profitability.

We develop portions of our clinical software system in-house. Failure of, or problems with, our system could harm our business and operating results.

We develop and utilize a proprietary clinical software system to collect assessment data, log patient visits, generate medical orders, and monitor treatments and outcomes in accordance with established medical standards. The system integrates billing and collections functionality as well as accounting, human resource, payroll, and employee benefits programs provided by third parties. Problems with, or the failure of, our technology and systems could negatively impact data capture, billing, collections, and management and reporting capabilities. Any such problems or failures could adversely affect our operations and reputation, result in significant costs to us, and impair our ability to provide our services in the future. The costs incurred in correcting any errors or problems may be substantial and could adversely affect our profitability.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 6. EXHIBITS.



2.1	Agreement and Plan of Merger, dated as of November 15, 2017, by and among LHC Group, Inc., Hammer Merger Sub, Inc., and Almost Family, Inc. (previously filed as Exhibit 2.1 to LHC Group's Form 8-K filed on November 16, 2017).

3.1	Amended and Restated Certificate of Incorporation of LHC Group, Inc. (previously filed as an Exhibit 3.1 to ~~the~~LHC Group’s Form ~~S-1/A (File No. 333-120792)~~8-K filed on ~~February 14, 2005)~~April 2, 2018).

3.2	Bylaws of LHC Group, Inc. as amended on December 31, 2007 (previously filed as Exhibit 3.2 to ~~the~~LHC Group’s Form 10-Q filed on May 9, 2008).

4.1	Specimen Stock Certificate of LHC Group’s Common Stock, par value $0.01 per share (previously filed as Exhibit 4.1 to ~~the~~LHC Group’s Form S-1/ A (File No. 333-120792) filed on February 14, 2005).

10.1	~~Amendment~~Senior Secured Credit Facility, dated March 30, 2018, between LHC Group, Inc., the Lenders Party Thereto, JPMorgan Chase Bank, N.A., and Capital One, National Association (previously filed as Exhibit 10.1 to LHC Group’s Form 8-K filed April 2, 2018).

10.2	LHC Group, Inc. ~~Second Amended and Restated 2005 Non-Employee Directors Compensation~~2018 Incentive Plan ~~effective January 20, 2015.~~(previously filed as Appendix A to LHC Group's definitive Proxy Statement on Schedule 14A filed on April 27, 2018).

31.1	Certification of Keith G. Myers, Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2	Certification of Joshua L. Proffitt, Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*	Certification of Chief Executive Officer and Chief Financial Officer of LHC Group, Inc. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS	XBRL Instance Document

101.SCH	XBRL Schema Document

101.CAL	XBRL Calculation Linkbase Document

101.DEF	XBRL Definition Linkbase Document

101.LAB	XBRL Label Linkbase Document

101.PRE	XBRL Presentation Linkbase Document

* This exhibit is furnished to the SEC as an accompanying document and is not deemed to be ~~��filed”~~“filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, and the document will not be deemed incorporated by reference into any filing under the Securities Act of 1933.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



		LHC GROUP, INC.

Date: ~~November 6, 2017~~August 2, 2018		/s/ Joshua L. Proffitt
		Joshua L. Proffitt
		Executive Vice President and Chief Financial Officer (Principal financial officer)

3844



Consideration
Cash	$	71,677
Fair value of total consideration transferred
Recognized amounts of identifiable assets acquired and liabilities assumed:
Patient accounts receivable	6,532
Trade name	13,953
Certificates of need/licenses	16,447
Other identifiable intangible assets	6
Other assets and (liabilities), net	2,121
Total identifiable assets	39,059
Noncontrolling interest	52,492
Goodwill, including noncontrolling interest of $34,313	$	85,110



	Home health reporting unit			Hospice reporting unit		Community - based reporting unit		Facility-based reporting unit		Total
Balance as of December 31, 2016	$	210,839		$	64,234	$	18,820	$	13,424	$	307,317
Goodwill from acquisitions	29,448			15,188		4,285		1,876		50,797
Goodwill related to noncontrolling interests	20,781			9,674		2,856		1,002		34,313
Goodwill related to disposals	(80		)	—		—		—		(80		)
Goodwill related to prior period net working capital adjustments............................................	(5		)	—		—		347		342
Balance as of September 30, 2017	$	260,983		$	89,096	$	25,961	$	16,649	$	392,689



	September 30, 2017
	Remaining useful life	Gross carrying amount		Accumulated amortization			Net carrying amount
Indefinite-lived assets:
Trade names	Indefinite	$	78,590	$	—		$	78,590
Certificates of need/licenses	Indefinite	49,773		—			49,773
Total		$	128,363	$	—		$	128,363
Definite-lived assets:
Trade names	2 months — 9 years	$	9,291	$	(7,184	)	$	2,107
Non-compete agreements	2 month — 2 years	5,732		(5,423		)	309
Total		$	15,023	$	(12,607	)	$	2,416
Balance as of September 30, 2017		$	143,386	$	(12,607	)	$	130,779



	December 31, 2016
	Remaining useful life	Gross carrying amount		Accumulated amortization			Net carrying amount
Indefinite-lived assets:
Trade names	Indefinite	$	64,672	$	—		$	64,672
Certificates of need/licenses	Indefinite	33,327		—			$	33,327
Total		$	97,999	$	—		$	97,999
Definite-lived assets:
Trade names	8 months — 9 years	$	9,294	$	(5,991	)	$	3,303
Non-compete agreements	2 months — 3 years	5,681		(4,977		)	704
Total		$	14,975	$	(10,968	)	$	4,007
Balance as of December 31, 2016		$	112,974	$	(10,968	)	$	102,006



	Number of shares	Per share price
Shares available as of December 31, 2016	189,611
Shares issued during the three months ended March 31, 2017	5,891	$	43.42
Shares issued during the three months ended June 30, 2017	4,152	$	51.21
Shares issued during the three months ended September 30, 2017..........................................................	4,775	$	64.49
Shares available as of September 30, 2017	174,793



Balance as of December 31, 2016	$	29,036
Additions	8,238
Deductions	(11,185		)
Balance as of September 30, 2017	$	26,089



Description	Rate per patient day
Routine Home Care days 1-60	$	190.55
Routine Home Care days 60+	$	149.82
Continuous Home Care	$	964.63
Full Rate = 24 hours of care
$40.19 = hourly rate
Inpatient Respite Care	$	170.97
General Inpatient Care	$	734.94



Payor	0-90		91-180		181-365		Over 365		Total
Medicare	$	78,600	$	14,145	$	2,725	$	6,196	$	101,666
Medicaid	5,507		2,588		614		1,393		10,102
Other	38,804		8,860		6,557		5,608		59,829
Total	$	122,911	$	25,593	$	9,896	$	13,197	$	171,597

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company